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Abstract 
 
The in vitro antiproliferative potential of three new oxorhenium complexes in particular 
compounds 1 ([ReO3(PTA)2][ReO4]) and 2 ([ReO3(HMT)2][ReO4]) bearing the 1,3,5-triaza-7-
phosphaadamantane (PTA) and the hexamethylenetetramine (HMT) ligands, respectively, and 
compound 3 ([ReO(Tpms)(HMT)]) bearing the tris(pyrazol-1-yl)methanesulfonate (Tpms) and HMT 
ligands, was evaluated in several cancer cell lines and fibroblasts. Compound 4, which is in a pending 
patent, bearing the trimeric polythiophene acetic acid (tPTAA) ligand, was also evaluated. 
The rhenium compound 2 showed the best results on the colorectal cancer cell line with a relative 
IC50 of 88.6 +/- 7.1 µM. 
 Combined therapy using compound 2 and doxorubicin lead to a reduction of ~1.5x in the 
percentage of cell viability compared to doxorubicin alone. The combined therapy with compound 4 
and cisplatin lead to a reduction of almost 3x in the percentage of cell viability compared with cisplatin 
alone. 
Based on the spectroscopic titration with calf thymus DNA and the results of the 
electrophoretogram with plasmid DNA is proposed that compound 2 interacts weakly with ct-DNA and 
it has a non-covalent mode of binding. Furthermore, the low binding constant ~105 suggests that the 
interaction between the metal complex and DNA might not be intercalative in nature.  
The fluorescence quenching assay of Human Serum Albumin showed a relatively moderate 
interaction between compound 2 and Human Serum Albumin with an average value of binding 
constant of the protein-quencher complex of 3.10 (+/- 1.2) x 103 M-1.  
According to the comparative proteomic results, colorectal cancer cells exposed to compound 2 
were more sensitive and prone to cell death due to alterations in the relative abundance of some heat 
shock proteins, a small GTPase and tubulin. On the other hand, Ezrin protein was more abundant on 
colon cancer cells exposed to compound 2 what could be an adaptive response inhibiting apoptosis. 
Proliferation-associated protein 2G4 overexpression might indicate that compound 2 triggers cell 
death by cell cycle arrest. 
Tumor cell death was also evaluated. According to the results of fluorescence microscopy, 
compound 4 was more effective in killing tumour cells than compound 2. Apparently, apoptosis is not 
the main mechanism of cell death for compound 2 with 4.15 +/-1.16 % of apoptotic cells by Hoechst 
staining assay and 1.4% of early apoptotic cells and 13.3% of late apoptotic cells for cells exposed to 
compound 2 in the flow citometry. 
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1 Introduction 
 
1.1 Cancer in numbers 
Cancer is one of the main causes of death. According to the World Health Organization, 8.2 
million people worldwide died from cancer in 2012, although the chemotherapeutic agents available 
(International Agency for Research on Cancer (IARC), 2012). The trend for the Estimated Global 
Cancer Burden, according to the data since 1980 (Figure 1.1), is a considerable increase, even 
though the public health action by governments and health practitioners. In addition, current 
chemotherapeutic agents are highly toxic. This indicates the need of new pharmaceuticals with 
reduced toxicity and more effective therapeutics.  
 
Figure 1.1 Estimated Global Cancer Burden: number of new cases of cancer per year (adapted from IARC, 
2008). The figure shows data from 1980, 1985, 1990, 2000, 2002, 2008 and a prevision for 2030 (IARC, 2008). 
The difference between developed and developing countries is reflected on the incidence of 
specific types of cancer. Richer countries have incidence rates of cancer more than the double in 
relation to developing countries. Europe and America are the regions with the highest incidence of all 
forms of cancer. Lung (1.59 million deaths, 19.4% of the total), liver (745.500 deaths, 9.1% of the 
total), stomach (723.000 deaths, 8.8% of the total), colorectal (694.000 deaths, 8.5% of the total), 
breast (522.000 deaths) and prostate (307.000 deaths) cancers cause most of the deaths, worldwide. 
Lung Cancer is the most common and the deadliest cancer in the world mainly due to tobacco 
smoking, being women less affected by this particular type of cancer due to cultural reasons. 
Colorectal cancer is the third most common cancer in men (10 % of the total) and the second in 
women (9.2 % of the total) worldwide, and the deadliest type of cancer in Portugal (3797 deaths, 
15.7% of the total) (see Figure 1.2). 
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Figure 1.2 Estimated cancer mortality worldwide (columns) and in Portugal (line) (adapted from IARC, 2012). 
 
1.2 Cancer etiology 
Cancer is not a modern disease. However, the world is facing a situation without precedent as 
the proportion of older people and life expectancy increase throughout the world, what makes chronic 
diseases such as cancer more common nowadays. It is also important to observe that the potential 
economic and social costs of cancer rise sharply with age (WHO, 2011). This link between aging and 
cancer has been studied and some reasons were pointed. An increase in mutations is proposed as an 
aging mechanism mainly due to the accumulation of mutations in the nuclear genome (Kennedy et al., 
2012). The genomic instability generates random mutations, chromosomal rearrangements and 
dysregulation of epigenetic mechanisms that promote tumor progression (Berdasco and Esteller, 
2010). Some authors indicate the disruption of the correct functioning of telomerase and telomere 
length as other cause. Tumor cells can prevent the loss of telomeres by telomerase upregulation due 
to alterations in the function of proteins that interact or interfer with the telomeres at the level of 
chromatin (Blasco, 2005). Other links between aging and cancer are described elsewhere (Campisi, 
2013; Finkel et al., 2007). 
In addition, there is an increased exposure to etiological agents. External factors as well as 
internal factors (inherited mutations, hormones, immune conditions and mutations resulting from 
metabolism) may act together or in sequence to initiate cancer development (WHO, 2013). Tobacco 
smoke influence on lung cancer incidence and mortality was already mentioned before (see 1.1). 
Other examples are the bacterium Helicobacter pylori that predisposes to stomach cancer (Jemal et 
al., 2010) and the human papilloma virus that is responsible for infections that can originate cervical 
cancer (Subramanya et al., 2008). Additional causes are based on the eating habits and physical 
activity. It is estimated that one in every ten cancers in Western populations are due to an inadequate 
intake of vegetables and fruit and excessive consumption of red meat (Daniel et al., 2011; IARC, 
2003). Other studies corroborate these causes (Bao et al., 2013; Bravi et al., 2013; Kandaswami et al., 
2005). Pollution of air, soil and water (Berman et al., 2008; Abnet, 2007; Chen et al., 2004; Desai et 
al., 2004) and ionizing radiation (Robertson et al., 2013; Sethi et al., 2012; Krewski et al., 2005; Shinji 
et al., 2004; Pavia et al., 2003;) are other well known causes of cancer as described elsewhere.  
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1.3 Cancer biology and therapeutics 
There are several different kinds of cancer that can be included in four main groups: carcinoma, 
sarcoma, lymphoma/leukemia and cancers derived from cells of the nervous system. Both carcinomas 
and sarcomas are solid tumours. Carcinomas are solid malignant lesions originating in the epithelial 
tissue. Sarcomas are solid tumours of the connective tissue, such as bone and muscle. Leukemia and 
lymphoma are malignancies originating in haematopoeitic or immune cells that are found throughout 
the vascular system (Alberts et al., 2008). 
All groups of cancer have in common an abnormal cell proliferation that gives rise to a 
neoplasm, but not all give rise to a mass of cells, e.g. leukemia (Hutter, 2010). Malignant neoplasms 
show a high level of anaplasia (lack of differentiation), the ability of invading neighbouring structures 
and to spread through the lymphatic system and bloodstream to other organs originating secondary 
tumors through a process called metastazation (Alberts et al., 2008).  
The human tumorigenesis is considered a multistep process. Sustaining proliferative signaling, 
growth suppressors’ evasion, cell death resistance, replicative immortality, angiogenesis induction, 
invasion activation and finally metastasis formation are considered the main steps. They are acquired 
in different tumor types via distinct mechanisms and at different points during the course of the 
tumorigenesis. The tumor progression can be viewed as a sequence of clonal expansions, each of 
which is triggered by the accidental acquisition of somatic mutations that confers selective advantage. 
This advantageous mutant genotype enables their outgrowth and an eventual dominance in a local 
tissue environment (Hanahan and Weinberg, 2011). 
In terms of therapeutics, cancer can be treated by surgery, radiation, chemotherapy, hormonal 
therapy, and targeted therapy. An early detection of cancer results in a less expensive treatment and 
better results. While surgical resection and adjuvant therapy can cure well confined primary tumors, 
metastatic disease is largely untreatable because of their systemic nature and the resistance of tumor 
cells to existing therapeutic agents (Gupta and Massagué, 2006). However, molecular and cell-
biological details of the tumour progression process are emerging and influencing the therapeutics 
available (Valastyan and Weinberg, 2011). Surgery and radiotherapy dominated the field of cancer 
therapy into the 1960s until new data showed that combinating chemotherapy could cure patients with 
various advanced cancers (Vincent T. et al., 2008).  
Some important features in cancer biology and therapeutics will be briefly addressed. 
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1.3.1 Mutation acquisition  
The development of tumours from single cells that begin to proliferate abnormally, called tumour 
clonality, is one important characteristic of cancer. Although this single cell origin, some fundamental 
changes are needed in order to develop cancer. The development of cancer is viewed as a multistep 
process involving mutation and selection for cells with progressively increasing capacity for 
proliferation, survival, invasion, and metastasis (Hanahan and Weinberg, 2011; Cooper, 2000).  
Studies of colon carcinomas provide an example of tumour progression during the development 
of cancer (see Figure 1.3).  
 
Figure 1.3 Development of colon carcinomas (Adapted from Cooper, 2000). A single initially altered cell (A) 
begins to proliferate and gives rise to a proliferative cell population (B), which progresses first to benign 
adenomas (C) of increasing size (D) and then to malignant carcinoma (E and F). In this phase, cancer cells 
invade the underlying connective tissue and penetrate blood and lymphatic vessels, spreading throughout the 
body.  
The earliest stage of colon cancer is increased proliferation of colon epithelial cells (Cooper, 
2000). Tumour initiation, is thought to be the result of a genetic alteration leading to abnormal 
proliferation of a single cell. Cell proliferation leads to the development of a population of clonally 
derived tumour cells, such as a benign neoplasm (an adenoma or polyp in colon cancer). Tumour 
progression continues by additional mutations that occur within cells of the population of clonally 
derived tumour cells that leads to the growth of adenomas of increasing size and proliferative potential 
(Hanahan and Weinberg, 2011; Alberts, 2008; Cooper, 2000). Some considered pathways of genomic 
instability in colorectal cancer are mutations in DNA mismatch repair genes, leading to a DNA 
microsatellite instability phenotype; mutations in Adenomatous polyposis coli (APC) and other genes 
that activate Wnt pathway, characterized by chromosomal instability phenotype, and global genome 
5 
 
hypermethylation, resulting in switch off of tumor suppressor genes, indicated as CpG island 
methylator phenotype (Bogaert and Prenen, 2014; Mojarad et al., 2013). 
Some of these mutations confer a selective advantage to the cell, e.g. more rapid growth, and 
by a process called clonal selection, the descendants of this cell will consequently become dominant 
within the tumour population. Clonal selection during tumour development, also aids tumours 
becoming increasingly malignant (Hanahan and Weinberg, 2011; Alberts, 2008; Cooper, 2000).  
Malignant carcinomas then arise from the benign adenomas characterized by invasion of the 
tumour cells through the basal lamina into underlying connective tissue. In the connective tissue of the 
colon wall cancer cells continue to proliferate and spread. Then, the cancer cells penetrate the wall of 
the colon and invade other abdominal organs. In addition, the cancer cells invade blood and lymphatic 
vessels, allowing them to metastasize throughout the body (Cooper, 2000). In a molecular level, 
Epithelial-mesenchymal transition (EMT, see section 1.3.8) is an important early event involved in 
invasion and metastasis of colorectal cancer. Some alterations in EMT include vimentin 
hyperexpression that iniciates the molecular program, and genes involved in invasion such as N-
cadherin with a decrease expression of genes involved in epithelial cell adhesion such E-cadherin, 
and even its loss. Progression in colon cancer is also characterized by activating mutations in Ras 
genes and tumor growth factor action (Todosi et al., 2012).  
 
1.3.2 Proliferation barriers: oncogenes, cell senescence and tumor suppressors 
Genes important for cancer development can be grouped into two main classes. Genes in 
which a gain-of-function mutation promotes cancer are called proto-oncogenes. The mutant forms are 
called oncogenes. Oncogenes are cancer-promoting genes. Many of them are involved in the 
mitogenic signaling pathways. Genes of the second group are called tumour suppressor genes. A 
loss-of-function mutation in a tumour suppressor gene can contribute to cancer (Alberts, 2008). 
 Oncogene signaling deregulation is important for cell proliferation however there is no 
universal response to an increasing expression of oncogenes. In contradiction with the notion that 
elevated expression of oncogenes increases cancer cells proliferation and thus tumor growth, some 
studies indicates that excessively elevated signaling by RAS (Retrovirus associated sequence 
oncogene), MYC (v-myc avian myelocytomatosis viral oncogene homolog), and RAF (Raf-1 proto-
oncogene, serine/threonine kinase) oncoproteins can provoke induction of cell senescence and/or 
apoptosis (Collado and Serrano, 2010). Other function for oncogenes operating within tumor cells, 
such as Ras and Myc, is upregulating the expression of angiogenic factors that promote angiogenesis. 
Cell senescence is a protective barrier to neoplastic expansion. Senescence is a cell 
nonproliferative but viable state characteristic of premalignant tumor stages, but it is absent from 
malignant tumors. Tumor suppressors can induce or prevent senescence. Deletion of tumor 
suppressors PTEN (phosphatase and tensin homolog), VHL (von Hippel-Lindau), NF1 (neurofibromin 
1) and RB (retinoblastoma-associated) leads to excessive proliferative signaling and ultimately to 
senescence (Collado and Serrano, 2010). 
There are dozens of tumor suppressors, including, two tumor suppressors that encode the 
P53 and the RB proteins. They transduce growth-inhibitory signals that originate inside the cell and 
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the RB protein also integrates signals from extracellular sources. The ‘‘guardian of the genome’’, TP53 
(Tumour protein P53), is involved in preserving genomic integrity.  Depending of the context, P53 can 
stop the cell-cycle progression or trigger apoptosis, the last one in case of irreparable damages 
(Jackson and Bartek, 2009).  Although P53 and RB absence permits persistent cell proliferation they 
are not essencial. There are studies that reflect a functional redundancy that restrict replication of cells 
lacking these proliferation suppressors. Tumor suppressor genes, in addition to their cell-cycle 
progression interference, can also contribute to contact inhibition that is abolished in cancer cells. For 
example, the protein Merlin, the product of the gene NF2, by sequestering growth factor receptors, 
limits its ability to efficiently emit mitogenic signals (Curto et al., 2007). In this way, Merlin absence 
promotes cancer cells proliferation. 
As stated before, many oncogenes are involved in mitogenic signaling pathways. p38α is a 
tumour suppressor gene and is a mediator of Mitogen-activated protein kinase pathway,  involved in 
resistance to cisplatin, irinotecan and 5-fluorouracil chemotherapy in colorectal cancer patients. 
Despite its tumour suppressor activity in some tissues, the p38α pathway may also acquire an 
oncogenic role involving cancer related-processes such as cell metabolism, invasion, inflammation 
and angiogenesis (Grossi et al., 2014). 
There are some suggestions of therapeutic exploration of the pathways involving oncogenes 
and tumor supressors described by other authors (Shanker et al., 2011; Luo et al., 2009). 
 
1.3.3 Apoptosis, autophagy and necrosis 
Apoptosis, in which a cell contracts and is consumed by neighbors, is triggered by diverse 
stresses as signaling imbalances resulting from elevated levels of oncogene signaling and DNA 
damage. Apoptosis is divided into two pathways: the extrinsic apoptotic pathway (death receptor), 
involving the Fas ligand/Fas receptor that receives extracellular death-inducing signals and the 
intrinsic pathway (mitochondrial) that integrates a variety of signals of intracellular origin as those 
originated during radio- and chemotherapy. Apoptosis is tightly regulated by the balance between pro- 
and antiapoptotic proteins. In human cancers, overexpression of antiapoptotic proteins such as Bcl-2 
(B-cell CLL/lymphoma 2) and Bcl-xL (Bcl-2-like protein 1 isoform), or downregulation of proapoptotic 
factors such as Bax (bcl-2-like protein 4), Bim (Bcl-2-like 11) and Puma (Bcl-2 binding component 3) is 
observed (Bai and Wang, 2014).  
As stated before, Bcl-2 is an antiapoptotic protein. However, Zeestraten and co-workers 
reported that from studies on colorectal cancer patients to determine Bcl-2 expression, upregulation of 
Bcl-2 was related with better survival. The explanations rised for this is the fact that Bcl-2 can also 
exert a distinct negative influence on cell cycle progression, which can eventually slow down tumor 
growth. The role of Bcl-2 may also depend on disease stage (Zeestraten et al., 2013).  
Autophagy appears to represent another barrier that needs to be avoided during tumor 
development (White and DiPaola, 2009). However, nutrient starvation, radiotherapy, and certain 
cytotoxic drugs can induce elevated levels of autophagy that could be cytoprotective for cancer cells 
(White and DiPaola, 2009; Apel et al., 2009). The autophagic program enables cells to break down 
cellular organelles, such as ribosomes and mitochondria, allowing the resulting catabolites to be 
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recycled and thus used for biosynthesis and energy metabolism. Autophagy machinery has both 
regulatory and effector components (Levine and Kroemer, 2008) and there is a link between 
autophagy and apoptosis. Mice bearing inactivated alleles of the Beclin-1 gene or of certain other 
components of the autophagy machinery exhibit increased susceptibility to cancer (White and 
DiPaola, 2009; Levine and Kroemer, 2008). Beclin-1 is a member of the BH3-only subfamily of 
apoptotic regulatory proteins, and its BH3 domain allows it to bind the Bcl-2/Bcl-xL proteins. Stress-
sensor-coupled BH3 proteins can displace Beclin-1 from its association with Bcl-2/Bcl-xL, enabling the 
liberated Beclin-1 to trigger autophagy, much as they can release proapoptotic Bax and Bak (Bcl-2 
homologous antagonist/killer) to trigger apoptosis. 
In contrast to apoptosis and autophagy, necrotic cells swollen and explode releasing 
proinflammatory signals into the local tissue microenvironment, and in some circumstances under 
genetic control (Galluzzi and Kroemer, 2008). Necrotic cells can recruit immune inflammatory cells 
and promote cell proliferation given that immune inflammatory cells are capable of promoting 
angiogenesis, cancer cell proliferation, and invasiveness. Additionally, necrotic cells can release 
bioactive regulatory factors, such as IL-1a, which can directly stimulate neighboring viable cells to 
proliferate (Grivennikov et al., 2010). Consequently, necrotic cell death can also stimulate cell 
proliferation. Other authors show that although this contradictory effects, necrosis could have a 
fundamental role in tumor clearance by stimulating the innate immune response (Guerriero et al., 
2008). 
 In relation to anticancer therapeutics, apoptosis, necrosis, mitotic catastrophe, senescence, 
and autophagy are the main types of cell death and cytostatic mechanisms described so far (Guerriero 
et al., 2008). There are studies about some compounds to modulate the activity of Bcl-2 family 
members or inhibit negative regulators of caspases such anticancer peptidic compounds that induce 
apoptosis of tumor cells (Barras and Widmann, 2011). Other review highligths the development of 
small-molecule inhibitors targeting three major classes of antiapoptotic proteins (Bai and Wang, 2014). 
 New drugs could be designed for targeting the major players in autophagy however more studies are 
needed to better understand the relationship between autophagy and cancer (Lisiak et al., 2014).  
 
1.3.4 Inflammatory cells in tumor progression 
Although cancer cells actively evade from elimination by the immune system (Bindea et al., 
2010; Ferrone and Dranoff, 2010), inflammation can contribute to tumor progression. Tumor-
promoting inflammatory cells include macrophage subtypes, mast cells, and neutrophils, as well as T 
and B lymphocytes (Egeblad et al., 2010; DePalma et al., 2008; Johansson et al., 2008; Murdoch et 
al., 2008). Some of the signaling molecules released by inflammatory cells with tumor-promoting 
activity are the Epidermal Growth Factor (EGF), the angiogenic Vascular Endothelial Growth Factor 
(VEGF), chemokines, cytokines, proangiogenic and/or proinvasive matrix-degrading enzymes, 
including Matrix Metalloproteinase-9 (MMP-9), cysteine cathepsin proteases and heparanase (Qian 
and Pollard, 2010; Murdoch et al., 2008). Targeting regulators and mediators of inflammation is 
thought as one strategy for cancer treatment (Sun and Karin, 2014). 
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1.3.5 Cell energy metabolism changes 
In cancer cells some metabolic changes occur in order to support continuous cell growth and 
proliferation (Wu and Zhao, 2013; Negrini et al., 2010).  Even in the presence of oxygen, cancer cells 
can limit their energy metabolism to glycolysis. As cancer cells obtain less energy with glycolysis 
compared to mitochondrial oxidative phosphorylation, they upregulate glucose transporters such as 
Glucose transporter 1 (GLUT1), which increases glucose import into the cytoplasm (Jones and 
Thompson, 2009; DeBerardinis et al., 2008). Glycolytic fueling has been shown to be associated with 
activated oncogenes (e.g., RAS, MYC) and mutant tumor suppressors (e.g., TP53) (Jones and 
Thompson, 2009; DeBerardinis et al., 2008) whose alterations in tumor cells have been selected 
primarily for their benefits in promoting tumour progression. Other studies show tumours with two 
subpopulations of cancer cells that function symbiotically: one subpopulation consists of glucose-
dependent (‘‘Warburg-effect’’) and other subpopulation of cells that preferentially import and utilize the 
lactate produced by the first group (Kennedy and Dewhirst, 2010; Feron, 2009; Semenza, 2008).  
Some antineoplastic agents that have been used in the clinic for a long time – such as 5-
fluorouracil, methotrexate and gemcitabine – inhibit metabolic enzymes. This leads to the idea that 
some drugs that are currently licensed by the US Food and Drug Administration (FDA) for use in 
patients with metabolic disorders may exert antineoplastic effects. Other possible antineoplastic 
agents indicated are metformin, phenformin and fibrates (Galluzzi et al, 2013). 
 
1.3.6 Growth-promoting signaling and division deregulation 
Cancer cells have the ability of continual proliferation. The growth-promoting signals bind to 
cell-surface receptors, typically containing intracellular tyrosine kinase domains, to regulate the cell 
growth and division. Cancer cells can deregulate the growth-promoting signals by autocrine 
proliferative stimulation. Structural alterations in the receptor molecules or the constitutive activation of 
components of signaling pathways operating downstream of the receptors (that can happens by 
somatic mutations) can also facilitate chronic proliferation. Some tyrosine-kinase inhibitors have been 
introduced in cancer therapeutics (Leeuwen et al., 2014). Cancer cells may also send signals to their 
microenvironment (see 1.3.9) to stimulate normal cells within the supporting tumor-associated stroma 
supplying cancer cells with growth factors (Hanahan and Weinberg, 2011).  
Some authors also observed that members of the mitogen-activated protein kinase (MAPK) 
and phosphatidylinositol-3 kinase (PI3K) cascades are good targets for anticancer therapeutics, as 
some of these proteins are involved in the cell survival mechanisms (Mester and Redeuilh, 2008). 
Other protein alterations have been associated with several cancer types. These alterations can 
be useful as therapeutic targets. Among the heat shock proteins (HSP), HSP27, HSP70 and HSP90 
are the most studied stress-inducible HSPs. In particular, Hsp90 aids in the conformational 
development of more than two hundred proteins which are associated with all main steps of cancer 
(Audisio et al., 2014). Heat shock proteins are a family of conserved chaperones induced by cell 
stress such as that provoked by chemotherapeutic drugs or heat, between other physiological and 
environmental insults (Horváth and Vígh, 2010; Blank and Goodman, 2009). In cancer cells, the 
expression and/or activity of those three heat schok proteins is atypically high, and is associated with 
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increased tumorigenicity, metastatic potential of cancer cells and resistance to chemotherapy. When 
associated with some apoptotic factors, some heat shock proteins become anti-apoptotic proteins with 
the ability to block the cell death process (Horváth and Vígh, 2010; Multhoff and Hightower, 2011).  
However, some treatments can trigger the cell membrane accumulation of heat shock proteins 
and promote anti-tumour T cell response (Kroemer et al., 2013; Krysko et al., 2013). Altogether, 
HSP27, HSP70 and HSP90 are emergent targets for anticancer therapeutics.  
Other relevant target in anticancer therapeutics is the tubulin/ microtubule system due to its role 
in cell division. Drugs that interfere with microtubule function inhibit the proliferation of cancer cells by 
preventing the correct formation of the mitotic spindle (Pasquier and Kavallaris, 2008). Alterations in 
expression of tubulin isotypes, in the tubulin post-translational modifications, and in the expression of 
microtubule-associated proteins (MAPs) are thought to influence cellular responses to 
chemotherapeutics (Parker et al., 2014).  
Besides mitotic spindle assembly, Ran also regulates nuclear envelope formation and cell cycle 
checkpoint control. Ran is a small ras-related GTPase that controls the nucleocytoplasmic exchange 
of macromolecules across the nuclear envelope, and is overexpressed in a range of tumors, such as 
breast and renal. Oncogenic KRAS (Kirsten Rat Sarcoma viral oncogene) or PIK3CA 
(phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) mutations makes some 
tumors addicted to Ran expression. Decreasing the endogenous levels of Ran in the cell could have 
anti-mitotic effects and consequently contribute to the development of an effective cancer therapeutic 
(Matchett et al., 2014). 
Other possible targets are among the purine ring de novo synthesis pathways. The synthesis 
of the purine ring de novo is required when DNA is replicated. The requirement to synthesize new 
purines in differentiated cells is smaller because the salvage pathway “recycle” nucleotides to the 
everyday needs.In this way, de novo synthesis of the purine ring is low in differentiated cells. This all 
together make inhibitors of the purine de novo synthesis effective drugs against cancer (Adam T., 
2005).  
 
1.3.7 Angiogenesis 
Angiogenesis is activated early during the development of invasive cancers, causing normally 
quiescent vasculature to continually sprout new vessels that help sustain expanding neoplastic 
growths. Tumor neovasculature is marked by premature capillary sprouting, distorted and enlarged 
vessels, leakiness, and abnormal levels of endothelial cell proliferation and apoptosis (Nagy et al., 
2010). In addition, tumors exhibit diverse patterns of neovascularization depending on the interactions 
between cancer cells and the associated stromal microenvironment (Baeriswyl and Christofori, 2009).  
 Angiogenesis is controlled by the level of inducing and opposing angiogenesis factors 
(Baeriswyl and Christofori, 2009). The most-known angiogenesis regulators and/or target proteins are 
vascular endothelial growth factor-A (VEGF-A), transforming growth factor (TGF)-, TGF-β and tumor 
necrosis factor (TNF)- as inducers, and thrombospondin- 1 (TSP-1), angiotensin, caveolin-1, -2 
endostatin and interferon-alpha as inhibitors (Hanahan and Weinberg, 2011). Some therapeutic 
peptides have been derived from these endogenous regulators (Rosca et al., 2011). Other regulators 
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include dominant oncogenes operating within tumor cells, such as Ras and Myc that can upregulate 
the expression of angiogenic factors, whereas in others, such inductive signals are produced indirectly 
by immune inflammatory cells (Wang and Miao, 2013; Hanahan and Weinberg, 2011).   
 
1.3.8 Metastasis formation 
Metastasis remains the major cause of mortality in patients with cancer. After angiogenesis 
and local invasion, distant metastasis formation is another step towards a higher grade of malignancy. 
The invasion-metastasis cascade is characterized by the invasion of epithelial cells of primary tumors 
into surrounding extracellular matrix and stromal cell layers (local invasion), entry into the lumina of 
blood vessels, transport through the vasculature (physical dissemination through lymphatic and 
hematogenous systems) and arrest at distant organ sites and into the parenchyma of distant tissues. 
In these distant sites the epithelial cells from the primary tumor form micrometastases, and in certain 
conditions re-initiate their proliferative programs, generating macroscopic tumors clinically detectable 
(Fidler, 2003).  
There are three types of invasiveness known: “mesenchymal”, “collective invasion” and 
“amoeboid” form of invasion. During the invasion-metastasis cascade cancer cells typically developed 
alterations in their shape as well as in their attachment to other cells and to the extracellular matrix 
(ECM). The Epithelial-Mesenchymal Transition (EMT) program regulates a particular type of 
invasiveness that has been named ‘‘mesenchymal’’. EMT is a program that can be activated 
transiently or stably, and to differing degrees (Hanahan and Weinberg, 2011). The transcriptional 
regulators Snail, Slug, Twist, and Zeb1/2 that are normally expressed during embryogenesis are also 
expressed in various combinations in the EMT program during tumor development. They are 
responsible for the loss of adherens junctions and associated conversion from a polygonal/epithelial to 
a spindly/fibroblastic morphology, expression of matrix-degrading enzymes, increased motility, and 
heightened resistance to apoptosis (Hanahan and Weinberg, 2011). Several of these transcription 
factors can directly repress E-cadherin (a cell-to cell adhesion molecule) gene expression, favoring 
invasion and metastasis (Peinado et al., 2004). Other forms of invasion are described elsewhere 
(Madsen and Sahai, 2010; Sabeh et al., 2009).  
Most of the studies on cancer are done in primary tumors even though primary tumors and 
metastases can differ in expression profiles. Targeting the outgrowth at a distant site (metastatic 
colonization), by targeting the metastatic cancer cell or the host cell, or by interrupting reciprocal 
interactions between tumor cells and the microenvironment are considered the most relevant 
therapeutics. Some target candidates are pointed elsewhere (Steeg and Theodorescu, 2008). 
 
1.3.9 Tumor Microenvironment 
Many human tumors are histopathologically heterogeneous, with various degrees of 
differentiation, proliferation, vascularity, inflammation, and/or invasiveness. In most tumors a subclass 
of neoplastic cells with varying abundance, named cancer stem cells (CSCs) are present (Cho and 
Clarke, 2008). Increasing evidence in a variety of tumor types suggests that cells with properties of 
CSCs are more resistant to various commonly used chemotherapeutic treatments (Singh and 
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Settleman, 2010). Being considered responsible for cancer initiation, progression, metastasis, 
recurrence and drug resistance, they are actracting attention for the development of new anticancer 
therapies (Chen et al., 2013). 
Other concerns are described elsewhere, such as “cancer-associated fibroblasts”, “cancer-
associated adipocytes” (Dirat et al., 2010; Pietras and Ostman, 2010; Rasanen and Vaheri, 2010; 
Shimoda et al., 2010) and dozens of microRNAs which are implicated in various tumor phenotypes 
and have been considered emerging targets in anticancer therapy (Garzon et al., 2010). 
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1.4 Metallic compounds and doxorubicin 
Metals are essential cellular components with unique characteristics that include redox activity, 
variable coordination modes, and reactivity towards organic substrates what makes the coordination 
complexes with a metal ion, good candidates for anticancer agents (Frezza et al., 2010).  
The type of metal bonded to carbon subdivides metallic compounds in two distinct types. One 
type involves compounds containing the main group elements such as the alkali and alkaline earth 
metals, and the more metallic elements in the zinc, boron, carbon, nitrogen, and oxygen vertical 
groups in the periodic table. The other type includes compounds containing transition metal elements. 
One of the features of transition metal chemistry that is not shared by main group elements is the 
potential for formation of metal-metal multiple bonds. This property of transition metals resulted in the 
foundation of coordination complexes with variable coordination modes (Martins et al., 2014; Hartinger 
and Dyson, 2009).  
To date, practically all transition and main group metals have been tested for antitumor 
properties. The antineoplastic potential of compounds of several metals such as gallium, ruthenium 
and titanium was recognized more than two decades ago. The number of metal compounds in current 
clinical use for the cancer therapy is extremely limited (Jakupec et al., 2008).  Platinum drugs are still 
the most used chemotherapeutic drugs (see section 1.4.1). Doxorubicin is not a metallic drug, but is 
also a reference chemotherapeutic drug (see section 1.4.2). 
  
1.4.1 Cisplatin 
Although the potential of the diverse metals in periodic table, cisplatin (Figure 1.4) impact 
influenced the antitumor agents development towards platinum compounds (Jakupec et al., 2008).  
 
 
Figure 1.4 The anticancer drug cisplatin (Adapted from Food and Drug Administration, 2011). 
 Platinum complexes such as cisplatin are clinically used as adjuvant therapy of cancers. 
Cisplatin is used to treat cancers including: sarcoma, small cell lung cancer, germ cell tumors, 
lymphoma, and ovarian cancer. Other platinum drugs include carboplatin, a drug with fewer and less 
severe side effects introduced in the 1980s, and oxaliplatin, a drug which is part of the FOLFOX (5-
FU, leucovorin, and oxaliplatin) treatment for colorectal cancer. Cisplatin is frequently given as part of 
a combination chemotherapy regimen with other drugs and it continues to find uses, especially as it is 
synergistic with other agents (Florea and Büsselberg, 2011). 
 Cisplatin damages tumors via inhibition of DNA synthesis and repair that might result in cell 
cycle arrest and therefore apoptosis will be induced. Neither cytotoxicity nor apoptosis are exclusively 
induced in cancer cells, thus, cisplatin might also lead to diverse side-effects such as neuro- and/or 
renal-toxicity or bone marrow-suppression. Other problem is that cancer cells could become cisplatin-
13 
 
resistant. To minimize or avoid this, combinatorial therapies are being developed (Florea and 
Büsselberg, 2011). 
 
1.4.2 Doxorubicin 
Doxorubicin (Figure 1.5) is an anthracycline antiobiotic without a metallic center but has 
shown great treatment potential, being regarded as one of the most potent of the Food and Drug 
Administration-approved chemotherapeutic drugs. The drug is a nonselective class I anthracycline, 
possessing aglyconic and sugar moieties (Tacar et al., 2012). 
Doxorubicin is given to treat non-Hodgkin's lymphoma, multiple myeloma, acute leukemias, 
Kaposi sarcoma, Ewing sarcoma, Wilm tumor, and cancers of the breast, adrenal cortex, 
endometrium, lung, ovary, and other sites. There are also some studies on colorectal cancer cell lines 
(Tacar et al., 2012). 
 Doxorubicin acts by binding to DNA-associated enzymes, such as topoisomerase enzymes I 
and II, and it can intercalate the base pairs of the DNA’s double helix. By binding to her targets a 
range of cytotoxic effects occurs in conjunction with the antiproliferative role, however this effect is 
limited by its toxicity on normal cells, being cardiotoxicity the major concern regarding the use of 
doxorubicin (Tacar et al., 2012). New therapies are needed to minimize the doxorubicin dose used in 
cancer treatment. 
 
 
Figure 1.5 The anticancer drug doxorubicin (Adapted from Inspiralis, 2006). 
1.4.3 Rhenium compounds 
In line with these problems, rhenium compounds have been studied for some imaging and 
therapeutic applications, (Bertrand et al., 2014; Lecina et al., 2014; Smilkov et al., 2014; Hanson et 
al.,2012; Wuest et al., 2012), including anticancer therapeutics.  
The chemistry of rhenium permits the existence of a large number of oxidation states ranging 
from +I to + VII. Current activity in the study of rhenium coordination chemistry has increased mainly 
due to radiopharmaceuticals. Some examples are the rhenium(V) complex of dimercaptosuccinic acid 
and mercaptoacetyltriglycine (MAG3) technetium system used as an agent for the treatment of a 
relatively rare medullary thyroid carcinoma (Yumata, 2010) and as an imaging agent for renal function, 
respectively. Other rhenium radiopharmaceuticals have been designed for various cancer tumours by 
labelling the radionuclide to steroids (Dilworth and Parrot, 1998). 
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The biodistribution and targeting ability of a compound are determined by a number of factors, 
such as the oxidation state of the metal, as well as the charge, polarity and lipophilicity of the complex. 
Some rhenium compounds are transported as perrhenate (ReO4-), which is the most stable, water-
soluble rhenium oxide in the +VII oxidation state (Yumata, 2010).  
Besides radiopharmaceuticals are derivatives of a nontoxic luminescent probe of rhenium 
applied for biological imaging that were discovered to have antitumor properties when irradiated at a 
suitable wavelength. Replacing just the 2,2’-bipyridine in 4 with 2-(2’-pyridyl)indolato and its 
derivatives (1–3) changes the physicochemical and biological properties of such rhenium(I) complexes 
(see Figure 1.6) making them toxic for cancer cells (Dieckmann et al., 2013). 
 
Figure 1.6 From luminescent (4) to light-induced anticancer Re complexes (adapted from Dieckmann et al., 
2013). 
Other rhenium compounds studied for their anticancer properties and lowest toxicity are 
described elsewhere (Collery et al., 2014; Kitanovic et al., 2014; Pracht et al., 2013; Wang et al., 2013; 
Collery et al., 2012; Martínez-Lillo et al., 2011) and provide a strong body of evidence that rhenium 
complexes could be effective anticancer agents, alone or in combination with other well established 
therapeutics. 
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1.5 Work subject and objectives 
 
Cisplatin, oxaliplatin, related metallodrugs as well doxorubicin are extensively used in the 
treatment of a diversity of cancers. However these drugs are highly toxic and tumor becomes drug-
resistance (Holohan et al., 2013). On the other hand, in addition to drug resistance there are also 
complicated side effects (Tacar et al., 2012). These facts indicate the need for cytotoxic agents with 
less toxicity, more tumour specific and devoid of drug resistance. New metallic compounds that could 
be more selective to cancer cells could fulfil these requirements.  
The present work is based on the latest studies of rhenium compounds and their anticancer 
therapeutic properties with alternative mechanisms of action and possible uses in combined 
therapeutics (Collery et al., 2014; Kitanovic et al., 2014; Pracht et al., 2013; Wang et al., 2013; Collery 
et al., 2012; Martínez-Lillo et al., 2011). 
 The cytotoxic potential of three new rhenium compounds [ReO3(PTA)2][ReO4] (PTA = 1,3,5-
triaza-7-phosphaadamantane), [ReO3(HMT)2][ReO4] (HMT = hexamethylenetetramine) and 
[ReO(Tpms)(HMT)]  (Tpms = tris(pyrazol-1-yl)methanesulfonate) designated from here on by 1, 2 and 
3,  and compound 4 was evaluated in several cancer cell lines and fibroblasts. The structure of 
compound 4, bearing the trimeric polythiophene acetic acid (tPTAA) ligand, can not be revealed due to 
a pending patent. The compounds 2 and 4 were also tested in combination with cisplatin and 
doxorubicin in tumor cell lines. Flash photolysis was used to assess transient species formation that 
could increase the anticancer potential (Dieckmann et al., 2013). 
The other objective was to deduce the mechanism of action and possible targets. For this, it 
was also analysed the capacity of the compound 2 to interact with Calf Thymus and plasmid DNA and 
Human Serum Albumin. The Two-dimensional Protein Electrophoresis technique was used to analyse 
the proteic extract of tumor cells after treatment with the compounds.  
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2   Materials and Methods 
2.1 Metalic compounds 
Rhenium compounds tested for antitumoral activity (see Table 2.1) were synthesized by Martins 
and collaborators (2013). They were prepared from the Re (VII) oxide Re2O7, which is a relatively 
inexpensive, accessible, and highly reactive material, and characterized by Infrared and Nuclear 
Magnetic Ressonance spectroscopies, elemental analysis and electrochemical properties as 
described by Martins and collaborators (2013). The same authors also have shown that the 
oxorhenium compounds are soluble in water, an ambivalent behavior which is characteristic of certain 
1,3,5-triaza-7-phosphaadamantane (PTA) Renhium complexes. 
 
Table 2.1 Oxorhenium complexes bearing the water-soluble tris(pyrazol-1-yl)methaneulonate, 1,2,5-triaza-7-
phosphaadamtane or related ligands. These organometallic compounds have been prepared from the Re(VII) 
oxide Re2O7 (Martins et al., 2013). In this table are represented from left to right: code (the number used in this 
thesis to refer a particular rhenium compound), formule, structure and molecular weight. 
Code Formule/ Structure Molecular Weight (gmol-1) 
(
1 
[ReO3(PTA)2][ReO4] 
(PTA = 1,3,5-triaza-7-phosphaadamantane) 
O
O
O
Re
N
N
N
P
N
N
N
P
ReO4
VII
 
 
 
 
 
 
830.8 
 
(
2 
[ReO3(HMT)2][ReO4] 
(HMT = hexamethylenetetramine) 
O
O
O
Re
N
N
N
N
N
N
N
N
ReO4
VII
 
 
 
 
 
 
796.8 
(
3 
[ReO(Tpms)-(HMT)] 
(Tpms = tris(pyrazol-1-yl)methanesulfonate) 
Re
N
N
N
N
N
N
CSO3
N
N
N
NO
III
 
 
 
 
 
635.7 
 
The  stock solutions of compounds 1 (12 036.6 µM), 2 (12 550.2 µM) and 3 (15 730.7 µM) 
were prepared by weighting 10 mg (Mettler Toledo, Greifensee, Switzerland) of each compound and 
dissolving them in 1 mL of dimethyl sulfoxide (DMSO, Sigma, St. Louis, United States of America), an 
organic solvent. Then they were divided in aliquots of 100 μL each. DMSO is the most common 
solvent used due to its good solvating ability for compounds, relative chemical inertness, and relatively 
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high boiling and freezing points. DMSO is also known by its antimicrobial activity, thereby avoiding the 
need for sterilization and autoclaving before use. The samples in DMSO can be stored either at room 
temperature or in a frozen state and thawed when needed (Cheng et al., 2003). In this work the 
aliquots were stored at -20ºC.  
Compound 4 was synthesized in University College of Dublin by Grace Morgan Group and its 
structure can not be revealed due to a pending patent. Compound 4 (4502.0 µM) was stored at 4ºC. 
 
2.2 Combined therapeutics 
The stock solution of cisplatin (3332.9 µM, Teva Parenteral Medicines, Inc., Teva 
Pharmaceuticals, Sellersville, United States of America) used in combined therapy with compound 2 
(see 2.1) was prepared by dissolving 1 mg of cisplatin USP and 9 mg of NaCl, in 1 mL of distilled 
water, pH 5.5, and stored at room temperature. Compound 4 was used in combined therapy with 
cisplatin and doxorubicin (8621.0 µM) separately. Doxorubicin was stored in aliquots of 100 μL at 4ºC.  
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2.3 Cell lines  
2.3.1 Tumour cell lines 
In this work eight tumour cell lines of Homo sapiens origin (see Table 2.2) were used 
(American Type Culture Collection (ATCC) nomenclature). 
 
Table 2.2 Tumoral cell lines that are used in this work. From left to right: the name, morphology, culture properties 
and cell line derivation and other informations. 
 
Tumoral Cell 
Lines 
 
Morphology 
 
Culture 
properties 
 
Derivation 
 
A549(1) 
 
epithelial 
 
adherent 
Initiated in 1972 through explant culture of lung carcinomatous 
tissue from a 58-year-old caucasian male. 
 
H1650(2) 
 
epithelial 
 
adherent 
Derived from stage 3B adenocarcinoma, in particular, 
bronchoalveolar carcinoma. The tissue donor was a 27-year-old 
caucasian male. 
 
 
H1975(3) 
 
epithelial 
 
adherent 
Established in July 1988 and is from an adenocarcinoma; non-
small cell lung cancer. The tissue donor was a female non-
smoker. 
 
 
HCT116(4) 
 
epithelial 
 
adherent 
This cell line is from colorectal carcinoma. The tissue donor was 
an adult male. 
 
HepG2(5) 
 
epithelial 
 
adherent 
This cell line is from hepatocellular carcinoma. The tissue donor 
was a 15-year-old caucasian male. 
 
K562(6) 
 
lymphoblast 
 
suspension 
The continuous cell line K-562 is from the pleural effusion of a 53-
year-old female with chronic myelogenous leukemia (CML) in 
terminal blast crisis. 
 
 
MCF-7/GFP(7) 
 
epithelial 
 
adherent 
MCF-7 was isolated (1970) from a malignant adenocarcinoma 
from the breast of a 69-year-old woman. The cell line MCF-7/GFP 
expresses GFP. 
 
 
MNT-1(8) 
 
epithelial 
 
adherent 
This is a melanotic cell line from skin enriched with mature stage 
III and IV melanosomes. 
Legend: More information in (accessed in November 29, 2013):  
(1)http://www.lgcstandards-atcc.org/Products/All/CCL-185.aspx#generalinformation;(2)http://www.lgcstandards-
atcc.org/products/all/CRL-5883.aspx?geo_country=pt;(3)http://www.lgcstandards-atcc.org/Products/All/CRL-
5908.aspx#generalinformation;(4)http://www.lgcstandards-atcc.org/Products/All/CCL-247.aspx; 
(5)https://www.lgcstandards-atcc.org/Products/All/CRL-10741.aspx;(6)https://www.lgcstandards-
atcc.org/Products/All/CCL-243.aspx;(7)https://www.cellbiolabs.com/sites/default/files/AKR-211-gfp-mcf-7-cell-
line.pdf; (8) http://www.lifetechnologies.com/pt/en/home/technical-resources/cell-lines/m/cell-lines-detail-545.html 
 
2.3.2 Normal cell line culture 
One normal cell line of Homo sapiens origin composed of adherent dermal fibroblasts from 
foreskin of a neonatal African American was used in this work (ATCC). The morphology is spindle-
shaped and cells are bipolar and refractile (http://www.lgcstandards-atcc.org/Products/All/PCS-201-
010.aspx). 
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2.4 Cell lines culture and harvesting  
Cell lines were cultured in Complete Culture Medium constituted by Dulbecco’s Modified Eagle 
Medium (DMEM; Invitrogen, New York, United States of America) supplemented with 10% (v/v) fetal 
bovine serum (FBS, Invitrogen, New York, United States of America), 1% (v/v) streptomycin-penicillin 
(Pen-Step+Antimycotic; Invitrogen) in culture flasks of 25, 75 and 175 cm2 (BD Biosciences, New 
Jersey, EUA). The culture flasks were incubated at 37℃ in a humidified atmosphere of 99% and 5% 
CO2. For the tumoral cell line HepG2 and dermal fibroblasts 1% (v/v) of MEM nonessential amino 
acids (100x, Invitrogen, New York, United States of America) were added to the Complete Culture 
Medium. 
 When cells were near the end of exponential growth (roughly 80% confluent), they were 
harvested with 6 mL, 4 mL or 1 mL of TrypLE (Gibco, Thermo Fisher Scientific, Waltham, United 
States of America), a replacement of Trypsin, (for 175 cm2, 75 cm2 or 25 cm2 flasks, respectively). 
After ten minutes TrypLE is neutralized with the same volume of Complete Culture Medium and cells 
were centrifugated at 1500 RPM for 5 minutes at 20ºC. Then the medium with TrypLE was aspirated 
and added new Complete Culture Medium, 1 or 2 mL to dissolve the pellet. The cell lines were 
subcultured at a 1:10 split ratio.  
 
2.4.1 Cell counting  
Cells were counted by the Trypan blue exclusion method in a hemocytometer (Hirschmann, 
Eberstadt, Germany) from a mixture of 350 μL of complete culture medium, 100 μL of Trypan blue at 
0.4 % (v/v) (Sigma, St. Louis, United States of America) and 50 μL of cellular suspension obtained 
during the subculturing process (see 2.4). A hemocytometer consists of a thick glass microscope slide 
with a grid of perpendicular lines etched in the middle. The grid has specified dimensions so that the 
area covered by the lines is known. The area under the coverslip fills by capillary action. The load 
volume is about 10 μL. The number of cells per ml is obtained by multiplying the number of total cells 
counted, the volume of the hemocitometer (104 mL-1) chamber and the dilution factor (10) divided by 
the number of squares counted, as represented in equation (1). 
(1) Total cells/mL =
Total cells counted x 104 x 10 
number of squares
 
 
2.5 Cell Viability assays 
To assess cell drug inhibition, 7500 cells per well were seeded in 96-well plates and incubated 
during 24 hours at 37ºC in a humidified atmosphere of 99% and 5% (v/v) CO2 in air. Drugs were 
added 24 hours later at established concentrations (between 0.1 μM and 1000 μM). Control cells used 
have been growth in the presence of 0.1% (v/v) DMSO at 99.5% (Sigma, St. Louis, United States of 
America). The 96-well plates were then incubated for 48 hours at 37ºC in a humidified atmosphere of 
99% and 5% (v/v) CO2. 
Cell viability was measured using the colorimetric method CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (Promega, Madison, United States of America) in 96-well assay 
plates. In this assay 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) is bioreduced by intracellular dehydrogenases present in metabolically active cells 
in the presence of the electron coupling reagent phenazine methosulfate (PMS) into a formazan 
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product that is soluble in tissue culture medium. The quantity of formazan product measured by the 
amount of 490nm absorbance is directly proportional to the number of living cells in culture. 
After 48 hours after drug addition, medium was aspirated from 96-well plates and 100 µL of a 
solution mixture of complete culture medium, MTS and PMS (100:20:1) were pipetted to each well. 
The 96-well plates were incubated at 37ºC and after 40 minutes the absorbance at 490 nm was read 
in a microplate reader (Tecan infinite F200, Männedorf, Switzerland). An illustrative scheme is shown 
in Figure 2.1. 
 
 
Figure 2.1 Illustrative scheme of cell viability assays. 7500 cells per well (0.75 x 105 cells/mL) were seeded in 96-
well plate at 37ºC, humidified atmosphere of 99% and 5% (v/v) CO2, and 24 hours later the cells were exposed to 
compounds for more 48 hours in the same conditions. Then, each well was aspirated and 100 µL of a solution 
mixture of complete culture medium, MTS and PMS (100:20:1) were pipetted to each well. After 40 minutes of 
incubation the absorbance at 490nm was read in a microplate reader. 
Data were treated by the equation (2) and the half maximal inhibitory concentration (IC50) 
determined by GraphPadPrism 6: 
(2)Cellular viability (%) =  
Absorbance 490nm (sample)
Absorbance 490nm (control)
 x 100% 
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2.6 Flash photolysis 
Laser Flash Photolysis experiments were carried out at room temperature on LKS.60 
Nanosecond Laser Flash Photolysis Spectrometer (Applied Photophysics, Surrey, United Kingdom) in 
two different solvents (distilled water solutions and deaerated distilled water solutions for at least 5 
minutes with oxygen-free nitrogen and methanol (99.9%, Sigma, St. Louis, United States of America)). 
The concentrations are adjusted to yield an absorbance of 0.2 at the excitation wavelength. Samples 
were excited by the 4th harmonic (λEXC = 266 nm, laser energy around 10 J) of a neodymium-doped 
yttrium aluminium garnet (Nd-YAG) laser. Light excitation was carried out using a medium pressure 
mercury arc lamp. Filters (Oriel, Bozeman, United States of America) were placed in the light path to 
narrow the spectrum and remove wavelengths inferior to 305 nm. Transient absorption spectra were 
recorded after the laser pulse (ten shots at each wavelength, with an interval of ten nanometers).  
Stock solutions of quenchers in the energy transfer assays were prepared so that it was only 
necessary to add microliter volumes (see Table 2.3) to the sample cell in order to reach appropriated 
quencher concentration. Benzophenone (10-4 mol/L) used in energy transfer assays was acquired 
from Merck, Whitehouse Station, United States of America. Data were acquired and analysed with the 
Applied Photophysics software.  
 
Table 2.3 Energy transfer assay table with volumes of compound 2 stock added to the quartz cuvette 
with benzophenone during the titulation.  
volume (µL) final concentration (M) 
0 0 
5 2.09 x10-5 
10 4.17 x10-5 
20 8.31 x10-5 
30 1.24 x10-5 
40 1.65 x10-4 
50 2.06 x10-4 
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DNA interaction assays 
 
2.7 Study of the interaction between compounds and pUC18 plasmid DNA 
2.7.1 Escherichia coli culture and DNA extraction 
Plasmid DNA (pDNA) extraction from pUC18 (Thermo Scientific, Waltham, United States of 
America), was done from Escherichia coli DH5 culture. Transformed cells stored at -80ºC were 
inoculated (20 µL) in an erlenmeyer (50 mL) with 20 mL of Luria-Bertani medium and 100 µg/mL of 
ampicillin (100 mg/mL, Bioline, Humber Road, United Kingdom). The culture was grown for sixteen 
hours with orbital agitation of 250 RPM at 37ºC. 
The NZYMiniprep kit (Nzytech, Lisbon, Portugal) was used to extract pUC18 pDNA. The 
procedure was followed according to manufacturer’s instructions, however some exceptions were 
performed: centrifugation times of 30 seconds was doubled for 1 minute and the elution step was 
made with 30 µL of Tris-HCl buffer (50 mM Tris-HCl (Merck, Whitehouse Station, United States of 
America), 10 mM NaCl (Panreac, Barcelona, Spain), pH 7.0) pre-warmed at 70ºC. 
The resulting pDNA was quantified by spectrophotometry at 260 nm (NanoDrop2000, Thermo 
Scientific, Waltham, United States of America). DNA purity is evaluated with the ratios Abs260/Abs280 
and Abs260/Abs230. Values of Abs260/Abs280 bellow 1.8 indicate protein contamination and above 2.0 
RNA presence. Values of Abs260/Abs230 bellow 2.0 indicate mainly alcohol contamination, and this ratio 
must be between 2.0 and 2.2. DNA integrity was assessed by agarose gel electrophoresis at 0.7 % 
(w/v) in TAE 1x (composition for 1 L of TAE 10x: 48.4 g of Tris-base, 3.72 g of EDTA, 11.42 mL of 
acetic acid, pH 8.0) with 1 % (v/v) GelRed (10000 x, Biotarget, Lisboa, Portugal). 
 
2.7.2 Plasmid DNA Electrophoretic procedure 
Each sample (20 µL) was prepared by mixturing 200 ng of pDNA pUC18, with the compounds 
(concentration between 0 and 200 µM) and Tris-HCl buffer (50 mM Tris-HCl, 10 mM NaCl, pH 7.0). 
Compounds were diluted in the same buffer before adding to the samples. A pDNA sample with 1.6 % 
(v/v) DMSO, instead of compound, was prepared as control. A sample of 200 ng of pDNA pUC18 was 
linearized with 0.5 µL of EcoRI (10 U/µL, Fermentas, Maryland, United States of America), 2 µL of 
EcoRI buffer (Fermentas, Maryland, United States of America) and destilled water until 20 µL.   
Samples were incubated during 24 hours at 37ºC. Then, they were deposited on an 
electrophoresis agarose gel 0.7 % (p/v) in TAE 1x buffer and run at 70 V during 90 minutes in a 
horizontal electrophoresis system. The DNA size marker used was λ DNA/HindIII (Fermentas, 
Maryland, United States of America). The agarose gel was stained in a solution of 100 mL of distilled 
water with ethidium bromide (Invitrogen) 0.04 % (v/v) during 15 minutes with agitation and visualized 
and images acquired with BioRad equipment and Quantity One software (BioRad, California, United 
States of America). Gel images were analysed by GelAnalyzer 2010 (http://www.gelanalyzer.com/). 
 
2.8 Spectrophotometric assays 
For compound-DNA interaction assessment absorption spectroscopy was done. The solution 
of DNA used was prepared by dilution (1:100) of Calf Thymus-DNA (Ct-DNA, Invitrogen, Carlsbad, 
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United States of America) stock in Tris-HCl buffer (50 mM Tris-HCl (Merck, Whitehouse Station, 
United States of America), 10 mM NaCl (Panreac, Barcelona, Spain), pH 7.0). Ct-DNA was quantified 
by spectrophotometry at 260 nm (NanoDrop2000, Thermo Scientific, Waltham, United States of 
America). 
Samples of different concentrations of Ct-DNA (2 µM to 84 µM) were prepared by pippeting 
diferent volumes from the stock solution (1:100). Then 200 µM of compound 2 or 1 µM of 4 or DMSO 
were added. 70 µL of Tris-HCl buffer and destiled water was added to make up 100 µL. DMSO 
absorbance was discounted from the obtained data. Samples were incubated during 24 hours at 37ºC. 
Then the U.V./Visible spectrum was acquired between 230 nm and 500 nm (UVmini-1240 UV-Vis 
Shimadzu spectrophotometer, Kyoto, Japan) for 80 µL of each sample. 
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Protein interaction assays 
 
2.9 Human Serum Albumin interaction assays 
Human Serum Albumin (HSA, Sigma, St. Louis, United States of America) stock solution was 
prepared diluting 100 mg of HSA in 10 mL of phosphate buffer (39 mL of 0.2 M monobasic sodium 
solution (Merck, Whitehouse Station, United States of America), 61 mL of  0.2 M dibasic sodium 
solution (Sigma, St. Louis, United States of America) and 100 mL of distilled water) with 0.15 M NaCl 
(VWR, Radnor, Pennsylvania), pH 7, incubating 1 hour at room temperature for full rehydration. 
Samples were prepared with 35 µM of HSA and varying the concentration of compound 2 (0 µM to 
720 µM). Then phosphate buffer was added to make up 100 µL. Samples were incubated during 24 
hours at 37ºC. The U.V./Visible spectrum was acquired between 230 nm and 500 nm (UVmini-1240 
UV-Vis Shimadzu spectrophotometer, Kyoto, Japan) for 80 µL of each sample and an emission 
spectrum between 300 nm and 500 nm after excitation at 295 nm (Varian Cary Eclipse Fluorescence 
Spectrophotometer, Agilent Technologies, Santa Clara, United States of America). 
 
2.10 Proteomic assay 
2.10.1 Cell culture and lysis 
Two-dimensional electrophoresis was used in this work for the analysis of protein mixture 
extracted from HCT116 cells after compound treatment. The technique allows to separate proteins 
according to two independent chemical properties in two steps: first Isoelectric focusing (IEF, see 
2.10.5), which separates proteins according to their isoelectric points, and the second step Sodium 
Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE, see 2.10.6), which separates them 
according to their Molecular Weights (MW). 
In a 175 cm2 culture flask, HCT116 cells (2 x 105 cells/mL) in Complete Culture Medium were 
incubated during 24 hours at 37ºC in a humidified atmosphere of 99% and 5% (v/v) CO2 in air for cell 
adherence. After 24h compounds were added after aspirating the medium and cells were incubated 
for 48 hours at 37ºC in a humidified atmosphere of 99% and 5% (v/v) CO2. As a control cells were 
incubated in the presence of 0.1% (v/v) DMSO (99.5%, Sigma, St. Louis, United States of America).  
After the 48 hours of incubation cells were harvested (see 2.4) to microcentrifuge tubes (1.5 
mL) and washed 2 times with PBS 1x. Lysis buffer (see Annex, Table 6.1) was applied in a proportion 
of 100 µL for 1 x 106 cells/mL. Cell lysis was accomplished with the aid of a sonicator (Hielscher 
UTR200, Teltow, Germany). First, five cycles of five pulses at 60% amplitude, second ten cycles of ten 
pulses at 70% amplitude and finally ten cycles of fifteen pulses at 80% amplitude, all of them at 0,5 
cycles and 30 seconds of interval on ice between each group of pulses. Afterwards, lysated samples 
were seen at microscope to confirm the lysis. In the end, samples were centrifugated first at 500 xg 
during 5 minutes at 4ºC to remove debris. The supernatant was recovered to a new microcentrifuge 
tube to centrifugate again at 9000xg during 10 minutes at 4ºC and stored at -80ºC. 
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2.10.2 Protein extract purification 
On the following day, samples were thawed on ice and about 8 hours later, 2-D Clean-up Kit 
(GE Healthcare, Little Chalfont, United Kingdom) was used to purify the samples, according to 
manufacturer’s instructions, but with some exceptions. 1 mL of cold (-20ºC) acetone was added to the 
pellet that was then dissolved by the aid of the vortex during 2 hours each 15 minutes. Afterwards, 
samples were left overnight at -20ºC. On the following day, the pellet was recovered at 12000 RPM 
during 15 minutes at 4ºC. Then 1 mL of cold (-20ºC) acetone was added. The pellet was dissolved 
with the aid of the vortex for 2 hours and recovered at 12000 RPM during 15 minutes at 4ºC. Pellet 
was left to dry and remove acetone at room temperature during 5 minutes. 
For protein rehydration 100 µL of rehidration buffer were used (see Annex,Table 6.2). Then it 
was thawed at room temperature and added prior use 0.1% DTT (10%, Promega, Madison, United 
States of America) and 1 mM PMSF (100 mM, Sigma, St. Louis, United States of America). Samples 
in rehidration buffer stayed at room temperature for 2 hours. Samples were then centrifugated at 
14000xg during 15 minutes to recover the supernatant where the soluble protein extract was. 
 
2.10.3 Total protein quantification 
For total protein quantification Pierce 660nm Protein Assay (Thermo Scientific, Waltham, 
United States of America) was used. The assay is based on the binding of a deprotonated dye-metal 
complex to positively charged amino acid groups in proteins, in acidic conditions, causing a shift in the 
dye’s absorption maximum measured at 660nm. This dye interacts mainly with basic residues in 
proteins. 5 µL of each protein extract, 45 µL of distilled water, and 750 µL of Pierce reagent (Thermo 
Scientific, Waltham, United States of America) were mixed by the aid of a vortex.  The absorbance of 
each sample was read at 660 nm (Nanodrop2000, Thermo Scientific, Waltham, United States of 
America) and compared to a standard curve (125 to 1000 μg/mL of Bovine Serum Albumin, BSA, 
Thermo Scientific, Waltham, United States of America).The volume corresponding to 200 µg of total 
protein was added to a new microcentrifuge tube. 
 
2.10.4 SDS-PAGE for assessment of compound quantification  
Compound interference in Pierce quantification was assessed by comparing the SDS-PAGE 
results of samples with or without compound treatment.  
The volume corresponding to 20 µg of total protein was mixed with a solution of 1x SDS 
loading buffer (4%, see Annex, Table 6.3) and 0.1% of DTT (10%, Promega, Madison, United States 
of America) and left overnight at room temperature. On the following day, the supernatant was 
recovered at 10000xg during 15 minutes. The samples were loaded in a poliacrilamide gel (see 
Annex, Table 6.4) and run at 130V (BioRad, California, United States of America, see Table 6.5) until 
the bromophenol blue arrived at the end of the gel. 
Gels were stained in a 100 mL solution of comassie blue R-350 (see Annex, Table 6.6). Gels 
in this solution were warmed in the microwaves during 2 minutes at 450 W, and rested 30 minutes on 
low horizontal agitation. In order to remove the excess of staining, the staining solution was 
substituted by Milli-Q water. This process was repeated until the excess is removed. 
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2.10.5  First dimension: IEF  
0.5 % (v/v) of DeStreak Reagent (GE Healthcare, Wilmington, United States of America) and 
0.5 % (v/v) of IPG pharmalyte pH 3-10 (GE Healthcare, Wilmington, United States of America) were 
added to 200 ng of protein in 125 µL of rehydration buffer.These samples were loaded on a ceramic 
support with an Immobiline DryStrip pH 3-10 NL of 7 cm (GE healthcare, Wilmington, United States of 
America). Afterwards, about 750 µL of Drystrip Cover Fluid (GE Healthcare, Wilmington, United States 
of America) were added. Samples were placed in Ettan IPGphor3 IEF System (GE Healthcare, 
Wilmington, United States of America) running the program in the Table 2.4: 
 
Table 2.4 Conditions of the Isoelectric Focusing program in Ettan IPGphor3 IEF System. Other parameters are 50 
µA per strip and 20 ºC. 
Step number Volts (V) Time (hour) 
1 30 14 
2 100 0,5 
3 500 0,5 
4 1000 0,5 
5 5000 1 
 
2.10.6 Second dimension: SDS-PAGE  
After Isoelectric Focusing, strips were placed in 5 mL of an equilibration solution (see Annex, 
Table 6.7) with 1% (p/v) of DTT (Promega, Madison, United States of America) during 15 minutes and 
then with a new equilibration solution with 2.5% (p/v) of iodoacetamide (GE Healthcare, Wilmington, 
United States of America) for more 15 minutes. 
Strips were placed in 12% poliacrilamide gels (see Annex, Table 6.4) and sealed with a 
solution of 0.5 % (p/v) of agarose (Fisher Scientific, Waltham, United States of America) in 
electrophoresis buffer with bromophenol blue traces (Riedel-de Haën, Saint Louis, United States of 
America). 
The same procedure that was described before (see 2.10.4) was used to run the samples, 
excepting the use of catodic buffer (1x of electrophoresis buffer (10x, see Table 6.5), 0.5% SDS (10%, 
p/v, Riedel-de Haën, Saint Louis, United States of America) and Milli-Q water) between the gels. 30 V 
were applied to ease protein transfer and then 80 V until the end of the gel. Gels staining procedure 
was described before (see 2.10.4). 
 
2.10.7 Gel Analysis 
The analysis of the protein abundancy levels was done by Melanie 7.0 software (Genebio, 
Geneva, Switzerland). First, spots were detected automatically and confirmed manually. Then, the 
match was made between spots of different gels. Each spot has a relative volume (% vol) obtained by 
Melanie 7.0 software. The abundancy level for each spot to DMSO (0.1%) control was calculated as 
shown in equation (3). 
(3)  
media of the relative volume of each spot on compound gels
media of the relative volume  of each spot on control gels
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 If abundancy level is equal or greater that 1.5 it indicates more protein abundancy than the 
control, and if it is equal or less than 0.7 it indicates less protein abundancy. Spot identification was 
made by comparison with a reference gel, where some spots were previously identified by Matrix 
Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) Mass Spectrometry (at ITQB as 
collaboration). 
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Apoptotic potential assessment 
 
2.11 Hoechst 33258 staining 
Hoechst 33258 nucleic acid stain is a fluorescent probe that emits blue fluorescence (461 nm) 
when bound to dsDNA. Apoptotic potential was assessed for compounds 2 and 4 in the HCT116 
carcinoma cell line. Culture plaques of 35 mm2 with a square microscope slide cover glass in the 
center were seeded with 2 mL of 0.75 x 105 cells/mL solution and incubated during 24 hours with 37ºC, 
5% (v/v) CO2 and 99% of relative humidity to allow cell adherence. Then, the medium was aspirated 
and the compounds or 0.1 % of DMSO (control) (diluted in 2 mL of complete culture medium) were 
added. After 48 hours of incubation in the presence of the compounds or DMSO, cells were washed 3 
times with PBS 1x (Invitrogen, Carlsbad, United States of America), fixed by adding 1 mL of a cold 
solution of paraformaldehyde 4 % (v/v) in PBS 1x and incubated at room temperature during 10 
minutes in the dark. Cells were washed with 1 mL of PBS 1x, three times. A staining solution in the 
proportion of 2 μL of Hoeschst 33258 (5 mg/ mL, Sigma, St. Louis, United States of America) in 1 mL 
of PBS 1x was prepared and added to each plaque and incubated at room temperature during 15 
minutes in the dark. Cells were washed with 1 mL of PBS 1x, three times. Afterwards 10 µL of a 
glycerol solution in PBS 1x in the proportion of 1:3 (v/v) was added to a microscope slide, and the 
microscope slide cover glass mounted carefully on the top with the cells glass face down. The 
compound 2 preparation was observed at the Olympus DP50 BX51 fluorescence microscope 
(Olympus, Tokyo, Japan) and the images acquired with the Olympus software. The compound 2018-
5-3 preparations were observed at the Leica DFC480 DMLB fluorescence microscope (Leica, Solms, 
Germany) and the images acquired with the IrfanView software. 
 
2.12 Flow cytometry 
Flow citometry was used in this work to assess cell death. HCT116 cells were plated into 35 
mm dishes at 1.5x105 cells per plate. Culture medium was removed 24 h after platting and replaced 
with 2 mL of fresh medium in the following conditions 1 to 5: 0.1% (v/v) DMSO (vehicle control) or (1) 
86.5 µM of compound 2 or (2) 0.25 µM or (3) 0.42 µM of doxorubicin, or (4 and 5) doxorubicin and 
afterwards compound 2 for more 24 h. Cells were incubated and then stained with fluorescein 
isothiocyanate (FITC) labeled annexin V and propidium iodide (PI) (Invitrogen, Carlsbad, United 
States of America) by the following procedure. After 48 hours of incubation, cells were harvested at 
1500 RPM for 5 minutes and washed 2 times with PBS 1x.100 µL of 1x Anexin V binding buffer (10x) 
in distilled water, 5 µL of Anexin V FITC and 2 µL of propidium iodide were added to the pellet of all 
samples. Then, samples were incubated at room temperature in the dark during 15 minutes. 400 µL of 
1x Anexin V binding buffer and 500 µL of PBS1x were added. Samples were read in a flow cytometer 
Attune® Acoustic Focusing Flow Cytometer (Life Technologies, Carlsbad, California), acquiring 10000 
events per sample. The results were analysed with Attune v2.1 (Applied Biosystems) software. 
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3 Results and Discussion 
3.1 Antiproliferative activities 
The experimental work was initiated with the viability assays that are used to determine if the 
compounds have effect on cell proliferation or show direct cytotoxic effects that could lead to cell 
death (Riss et al., 2013). In order to assess cell viability in response to compound treatment, the 
metabolic MTS assay was chosen. This assay measures mitochondrial enzymatic activity that occurs 
only in viable and proliferating cells (McGowan et al., 2011). 
The rhenium compounds were tested in nine different cell lines (Figure 3.1 to Figure 3.9). The 
values of relative IC50 were calculated from the analysis of dose-response curves obtained with the 
data from the Figure 3.1 to Figure 3.9. The relative IC50 is given by the compound concentration 
corresponding to the midpoint between the top and bottom plateaus of the dose-response curve. The 
bottom plateau is due to the background absorbance of the assay reagents at 490 nm and the 
calculus of relative IC50 is one way of overcome this technical interference. The values of absolute IC50 
could be obtained directly from the data since it is the value that corresponds to 50% on the right axis 
(GraphPad, 2010).  
Compared to compound 1 and 3, compound 2 showed  a higher  antiproliferative activity in all 
the cell lines tested (Figure 3.1 to Figure 3.9) and in particular the most promising results were 
obtained in HCT116 (IC50 of 88.6 µM +/- 7.1) and MNT-1 (IC50 of 57.6 µM +/-9.1) cell lines (Figure 3.1 
and Figure 3.9, respectively). Interestingly, a smaller cytotoxic effect of compound 2 in normal 
fibroblasts was observed (Figure 3.2).  Even at 88.6 µM (IC50 of HCT116) of compound 2, cell viability 
in fibroblasts is ~100% (Figure 3.2).  
 
Figure 3.1 Cell viability assays in HCT116 cell line after 48 hours of treatment with compounds 1, 2 and 3. Cell 
viability was assessed by the MTS assay. The values shown correspond to media of three independent 
assays.The error bars correspond to the standard error of the mean (*p<0.05 in relation to 500 µM and 1000 µM 
of compound 1 and 3, and *p<0.05 in relation to 100 µM, 500 µM and 1000 µM for compound 2). Cell viability 
values were normalized to the control cells (no added compounds; presence of DMSO 0.1%). 
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Figure 3.2 Cell viability assay in fibroblasts after 48 hours of treatment with compounds 2 and 3. Cell viability was 
assessed by MTS assay. The values shown correspond to media of three independent assays for compound 2 
and two independent assays for compound 3. The error bars correspond to the standard error of the mean 
(*p<0.05 in relation to 100 µM of compound 3). Cell viability values were normalized to the control (no added 
compounds; presence of DMSO 0.1%).  
 
In the present study, the Selectivity Index (SI) can not be calculated for compound 2. 
Selectivity Index is the result of the ratio between the IC50 of the compound in a normal cell line 
(fibroblasts) and the IC50 of the same compound in the cancer cell line (e.g. HCT116) (Badisa et al., 
2010).  The range of concentrations tested on fibroblasts was not enough to determine the 
corresponding IC50. However could be expected a SI higher than 1. This is an important property for a 
chemotherapeutic drug since side-effects may be minimised. 
Besides our results, Ho and co-workers synthesised [ReBr(CO)3(SSC)] [SSCs = 
semicarbazones] complexes that exhibited moderate to high cytotoxicities towards MOLT-4 cells from 
acute lymphoblastic leukemia (IC50 = 1–24 μM), and the majority of them were almost non-toxic 
against normal human fibroblasts. Displacement of the SSC ligand is probably not involved in the 
mechanism of cytotoxicity of rhenium salicylaldehyde semicarbazone complexes, but interaction with 
biomolecules after loss of bromide is plausible (Ho et al., 2013).  
It is worth of note the importance of the ligands in the antitumour complex antiproliferative 
activities. Comparing the results abserved for compound 1 (IC50 of 213.9+/-15.9 µM), with the more 
hydrophilic 1,3,5-triaza-7-phosphaadamantane (PTA) ligand, and compound 2 (IC50 of 88.6+/-7.1 µM), 
with the same structure but instead of PTA with the ligand hexamethylenetetramine (HMT), it could be 
said that the HMT ligand is more effective in a antitumour compound than the PTA ligand. However, 
Scolaro and co-workers showed some promising results for compounds with PTA ligands by 
comparing the in vitro and in vivo activity and cytotoxicity of a series of RAPTA-type complexes 
bearing PTA ligands (Scolaro et al., 2005). It was demonstrated that these compounds are active and 
selective towards the metastasizing mouse cell line (TS/A) from mammary adenocarcinoma. Other 
compounds with PTA ligands such as [C5H5Rh(PTA)Cl2] and [Os(ƞ6-p-C10H14)Cl2(PTA)] demonstrated 
cytotoxicity activity in the HT29 colon cell line. A possible explanation is as cancer cells display lower 
pH values (<6) than healthy ones, PTA would protonate at low pH values and hence showing selective 
DNA damage for cancer cells (Scolaro et al., 2005).  
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On the other hand, Scolaro and co-workers in other experiments showed that in some 
situations more hydrophilicity could be detrimental. The insertion of functional groups such as amines 
on the arenes of RAPTA-type compounds and formation of cationic complexes with BF4 was tested in 
order to enhance hydrogen bonding with DNA. RAPTA-type compounds possess a modular structure 
comprising a ruthenium-bound arene, one PTA molecule and two halides and are known for their 
antitumour activity. Cell viability studies using the metastasizing mouse cell line TS/A from mammary 
adenocarcinoma were compared to the nonfunctionalized analogues. These structural alterations 
resulted in a decrease in toxicity towards cancer cells being a possible explanation the increasing 
hydrophilicity detrimental to drug uptake (Scolaro et al., 2006).  
Those studies show that there must be a compromise between hydrophilicity and 
hydrophobicity to an effective antitumour effect and in the present study this is achieved by compound 
2.  
In addition to these observations, is known that the metal center of the complex, even with 
similar ligands, have an important role. The trans-platinum thiolate complexes bearing PTA or DAPTA 
ligands trans-[Pt(SR)2(P)2] [P = PTA, SR = 2-thiopyrimidine, 2-thiopyridine; P = DAPTA, SR = 2-
thiopyrimidine, 2- thiopyridine] and gold(I) complexes [Au(SR)(PR’3)] (SR = various thiolato 
derivatives; PR’3 = PTA, DAPTA) were tested for in vitro cytotoxicity against seven human cancer cell 
lines. Au(I) complexes showed low cytotoxicity, while the Pt(II) complexes demonstrated high 
cytotoxicity for almost the cells lines, including colon cancer cell line (Miranda et al., 2008). It would be 
interesting to study similar changes for the present rhenium compounds since it could better elucidate 
the structure-activity relationship and the importance of the metal center. 
The results of cell viability assay in the chronic myelogenous leukemia cell line K562 after 48-
hour treatment with the rhenium compounds are represented in Figure 3.3. 
 
Figure 3.3 Cell viability assay in K562 cell line after 48 hours of treatment with compound 1, 2 and 3. Cell viability 
was assessed by MTS assay. The values shown correspond to media of three independent assays, excepting the 
cell viabilities for treatment with 10 and 20 µM concentrations of compound 1 and cell viabilities.The error bars 
correspond to to the standard error of the mean (*p<0.05 in relation to 50 µM of compound 1, *p<0.05 in relation 
to 10, 20 and 50 µM for compounds 2 and 3). Cell viability values were normalized to the control: (no added 
compounds; presence of DMSO 0.1%). 
Although the unsatisfactory response of the chronic myelogenous leukemia cell line to the 
rhenium compounds in the present work, Parson and co-workers tested other rhenium compounds 
with promising results in which the rhenium atom is octahedrally coordinated to a chelated (bidentate) 
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polypyridyl ligand, three adjacent CO molecules, and a pentylcarbonate group [-OC(O)OC5H11] in a 
facial arrangement. According to the authors, the six drugs showed GI50 (GI50, 50% cell-growth 
inhibition) around 3-4 μM and an efficacy against all the cancer cells treated, including myeloid 
leukemia cancer cells, at a lower dose than the cisplatin (Parson et al., 2013a). These studies show 
once again that the ligands around the metal atom play an important role in the antitumour properties. 
The antiproliferative activities in lung adenocarcinoma cell lines (A549, H1650 and H1975) 
after 48-hour treatment with the rhenium compounds are represented on Figure 3.4, Figure 3.5 and 
Figure 3.6. 
Lung cancer is histologically classified into two major types, small cell lung cancer (SCLC) and 
nonsmall cell lung cancer (NSCLC). Approximately 85–90% of lung cancers are NSCLC being 
adenocarcinoma 40% of NSCLC (Gong et al., 2011). 
As far as the treatment of NSCLC is concerned, targeted therapies are mainly specific to the 
oncogenic tyrosine kinase pathways activated in tumour cells. For example, some receptor tyrosine 
kinase (RTK) pathway inhibitors, such as Sunitinib (Sutent) and Crizotinib are in clinical trials for 
NSCLC (Gong et al., 2011).  
The major problem in targeted therapy for NSCLC is to know the activated oncogenic 
pathways in the patient’s tumor so that the appropriate inhibitor(s) can be chosen (Gong et al., 2011). 
In this way there are a wide range of cell lines with different activated oncogenic pathways in order to 
study more efficacious treatments. H1975 shows a moderate activation of epidermal growth factor 
receptor2 (HER2), hepatocyte growth factor receptor (c-MET), and Src Homology 2 Domain 
Containing (SHC) pathways and a low activation of the insulin-like growth factor 1 receptor (IGF-1R) 
pathway. The metastatic bronchioalveolar carcinoma cell line H1650 shows a moderate activation of 
the HER1 and HER2 pathways.The large-cell carcinoma cell line A549 exhibits a moderate activation 
of the HER1 and IGF-1R pathways with a low activation of the c-MET and HER2 pathways (Gong et 
al., 2011). 
A549 cell line results for compound 2 (IC50 197.8 µM), the one with best results, shows that it 
is not efficacious in this adenocarcinoma cell line. Our results in H1975 and H1650 cell lines show a 
similar outcome for rhenium compounds. Indeed, Vock and co-workers studied a serie of compounds 
of general formula [Ru(6-pcymene)(R2acac)(PTA)][X] (R2acac =Me2acac, tBu2acac, Ph2acac, Me2acac-
Cl; X= BPh4, BF4 ) and demonstrated that tetrafluoroborate salts were less cytotoxic for A549 lung 
carcinoma than for the A2780 cells and the values of cytotoxicity were correlated to the lipophilicity 
parameters of the complexes (Vock et al., 2008).  
A549 cell line harbors the KRAS mutated gene. KRAS gene mutation is associated with 
resistance to HER1 tyrosine kinase inhibitors (Kobayashi et al., 2005; Paez et al., 2004). A549 don’t 
respond to treatment with HER1 inhibitors but it is sensitive to the downstream Phosphoinositide 3-
kinase (PI3K) inhibitor BEZ-235 (Gong et al., 2011). 
H1975, and H1650 lung tumor cell lines harbor the HER1 gene mutation and they are 
sensitive to HER1 inhibitor treatment. H1975 cells respond more effectively to a combination of 
HER1/2 RTK inhibitor BIBW-2992 with either MEK inhibitor PD-325901 or PI3K inhibitor BEZ-235 with 
almost 100% growth inhibition of this cell line at 10 μM concentration. A synergistic inhibition of H1650 
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cell proliferation can be observed when it is treated with the irreversible HER1/2 inhibitor BIBW-2992 
in combination with one of the downstream inhibitor BEZ-235 or a combination of the two downstream 
inhibitors, PD-325901 and BEZ-235 (Gong et al., 2011). 
Combined therapy is a more efficacious way of eradicate a tumour, as it is indicated by the 
responses of lung cell lines to this known inhibitors. In this way, it would be important to try compound 
2 with an established drug on the lung cancer cell lines. 
 
Figure 3.4 Cell viability assay in A549 cell line after 48 hours of treatment with compounds 1, 2 and 3. Cell 
viability was assessed by MTS assay. The values shown correspond to media of three independent assays, 
excepting the cell viabilities for treatment with 10 and 20 µM concentrations of compound 1.The error bars 
correspond to the standard error of the mean (*p<0.05 in relation to 500 µM of compound 1, 2 and 3). Cell viability 
values were normalized to the DMSO control: (no added compounds; presence of DMSO 0.1%). 
 
Figure 3.5 Cell viability assay in H1650 cell line after 48 hours of treatment with compounds 2 and 3. Cell viability 
was assessed by MTS assay. The values shown correspond to media of two independent assays.The error bars 
correspond to the standard error of the mean. Cell viability values were normalized to the DMSO control: (no 
added compounds; presence of DMSO 0.1%). 
 
* *
*
* *
*
*
*
*
*
0
50
100
10 20 50 100 500
C
e
ll
 V
ia
b
il
it
y
  
(%
)
Compound concentration (μM)
A549 cell line 
compound 1
compound 2
compound 3
0
50
100
10 20 50 100
C
e
ll
 V
ia
b
il
it
y
  
(%
)
Compound concentration (μM)
H1650 cell line 
compound 2
compound 3
34 
 
 
Figure 3.6 Cell viability assay in H1975 cell line after 48 hours of treatment with compounds 2 and 3. Cell viability 
was assessed by MTS assay. The values shown correspond to media of three independent assays. The error 
bars correspond to the standard error of the mean (*p<0.05 in relation to 100 µM of compound 2). Cell viability 
values were normalized to the DMSO control: (no added compounds; presence of DMSO 0.1%). 
 
In Figure 3.7 we show the antiproliferative activity results for the breast cancer cell line, 
MCF7, after 48-hour treatment with the rhenium compounds. 
 
Figure 3.7 Cell viability assay of MCF7 cell line after 48 hours of treatment with compounds 2 and 3. Cell viability 
is assessed by MTS assay. The values shown correspond to media of three independent assays. The error bars 
correspond to the standard error of the mean (*p<0.05 in relation to 20 µM of compound 3). Cell viability values 
were normalized to the control: (no added compounds; presence of DMSO 0.1%). 
Concerning the viability results in mammary carcinoma (MCF7) cell line no effective 
antiproliferative effect was observed (Figure 3.7). However, rhenium compounds could be studied in 
combined therapy with selenium compounds, as suggested by other authors.Collery and co-workers 
studied a water-soluble rhenium diseleno-ether compound (with one atom of Re and two atoms of Se) 
in vivo and they also investigated the uptake of Re into the nucleus of malignant cells in culture. It was 
observed that a compound combining Re and Se in a single molecule, is able to deliver them to the 
organism via an oral route, for cancer treatment. It was also demonstrated that exposure to Rhenium 
diseleno-ether induced a Re uptake in the nucleus and there was no efflux of Re after a post- 
exposure period of 48 hours in MCF-7 cells. The explanations appointed for the success of the Re 
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diseleno-ether compound is its amphiphilic nature. Its solubility in water makes it easy to administer 
and its lipophilic properties allow a great diffusion across cell membranes (Collery et al., 2014).  
Other rhenium compounds were studied in MCF-7. Cabeza and co-workers studied 
complexes of rhenium(I) with some 5-nitrosopyrimidines with general formula [ReCl(CO)3L] that 
showed cytotoxic effects in all the cell lines used, including MCF-7(Cabeza et al., 2005). Other six 
novel rhenium pentycarbanato compounds were also presented by Parson and co-workers. The 
trypan blue assay revealed a significant cytotoxicity against the triple node negative breast cancer cell 
line HTB-132 and less toxicity than cisplatin in the Balb/c mouse kidney cell lines (Parson et al., 
2013b). Further studies are needed to discover the mechanism of action and structure-activity 
relationship of these rhenium compounds what could in addition explain the results of the compounds 
2 and 3 in the MCF7 cell line.  
 Similar results to MCF7 cell line are shown in hepatocellular cancer cell line HepG2 (Figure 
3.8). In contrast, besides the radioactive isotopes of rhenium, Wong and co-workers also studied the 
rhenium compound of formula [Re(CO)3(2-appt)Cl]  [2-appt = 2-amino-4-phenylamino-6-(2-pyridyl)-
1,3,5-triazine] that exhibited moderate cytotoxicities toward several cancer cell lines, including HepG2 
(Ma et al., 2007).  
 
Figure 3.8 Cell viability assay in HepG2 cell line after 48 hours of treatment with compounds 2 and 3. Cell viability 
was assessed by MTS assay. The values shown correspond to media of three independent assays. The error 
bars correspond to the standard error of the mean (*p<0.05 in relation to 100 µM of compound 3). Cell viability 
values were normalized to the control: (no added compounds; presence of DMSO 0.1%). 
 
As observed in the melanocitic cell line from the skin (MNT-1), the compound 2 with the 
hexamethylenetetramine (HMT) ligands show a better antitumour activity compared to compound 3 
with the tris(pyrazol-1-yl)methanesulfonate (Tpms)  ligand (Figure 3.9). 
Malignant melanomas are intrinsically resistant to many conventional treatments, such as 
radiation and chemotherapy (Chen et al., 2009). There is a radioactive rhenium compound, 188Re-6D2, 
in clinical trials for the treatment of melanoma. The data demonstrated that was well tolerated, 
localized in melanoma metastases, and had antitumor activity. The investigation is going on in patients 
with metastatic melanoma (Klein et al., 2013). 
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Although the interesting antiproliferative potencial of compound 2 in MNT-1 cancer cell line, 
studies were not continued due to the possible interference of its dark color in the colorimetric cell 
viability assays. 
The rhenium compound 1 with the PTA ligands was not tested on most of the cancer cell lines 
(HepG2, MNT-1, H1975, H1650). However, studies undertaken by Pettinari and co-workers with four 
silver(I) complexes of formulas [Ag(Tpms)], [Ag(Tpms)-(PPh3)], [Ag(Tpms)(PCy3)], and 
[Ag(Tpms)(PTA)] {Tpms = tris(pyrazol-1-yl)methanesulfonate, PPh3= triphenylphosphane, PCy3= 
tricyclohexylphosphane} showed antiproliferative activity, with IC50 between 0.42 µM and 12.35 µM, 
against human malignant melanoma (A375) with an activity often higher than that of AgNO3, which 
has been used as a control. The complex with less activity was [Ag(Tpms)(PTA)] whereas the other 
complexes without the PTA ligand showed higher cytotoxicity, even the complex [Ag(Tpms)] (Pettinari 
et al., 2011). Taking these results into consideration and our previous results in other cancer cell lines 
it is possible to expect that the rhenium compound 1 has lower cytotoxic potential. 
 
Figure 3.9 Cell viability assay in MNT-1 cell line after 48 hours of treatment with compounds 2 and 3. Cell viability 
was assessed by MTS assay. The values shown correspond to media of three independent assays. The error 
bars correspond to the standard error of the mean (*p<0.01 in relation to 100 µM of compound 2 and compound 
3). Cell viability values were normalized to the control: (no added compounds; presence of DMSO 0.1%). 
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The results are summarized in Table 3.1. 
 
Table 3.1 Cell viability assays results for rhenium compounds. The values shown correspond to media of three 
independent assays, excepting for H1650 cell line that are two independent assays. The IC50 value for compound 
2 in HCT116 is representend as IC50 +/- SEM. Half maximal inhibitory concentration (IC50) is determined by the 
software GraphPadPrism 6. 
  IC50 (µM)  
Cell line Compound 1 Compound 2 Compound 3 
A549 >100 >100 >100 
H1650 --- >100 >100 
H1975 --- ~100 >100 
HCT116 >100 88.6 +/- 7.1 >100 
HepG2 --- >100 >100 
K562 >100 >100 >100 
MCF-7/GFP --- >100 >100 
MNT-1 
Fibroblasts 
--- 
--- 
57.6 +/-9.1 
>100 
>100 
>100 
 
 
3.1.1 Combined therapeutics with compound 2 on colorectal cancer cell line 
The majority of cases of colorectal cancer diagnosed are in advanced stage. Adenomas and 
early stage colorectal cancers are often asymptomatic but potentially curable if early detected and 
removed while symptomatic colorectal cancers are mostly likely in advanced stage when detected and 
treatment options more complicated specially in metastatic tumors (Carethers, 2008).Therapy for 
advanced colorectal cancer can be divided into colon and rectal cancer components, with surgery as 
the main component of therapy for both subtypes. Rectal cancers are treated surgically by low anterior 
resection or abdominal perineal resection, often in combination with 5-fluoruracil (5-FU)-based 
chemoradiation. All the stages of the disease are generally treated with adjuvant or neoadjuvant 
chemotherapy, excepting Stage I disease that is approached with wide surgical resection. In stage I, 
cancer has formed in the mucosa (innermost layer) of the colon wall and has spread to the 
submucosa (layer of tissue under the mucosa) (Winslow, 2014). For colon cancers, is normal to use 
adjuvant 5-FU-leucovorin or FOLFOX (5-FU, leucovorin, and oxaliplatin) especially in stage III patients 
and FOLFIRI for stage IV colon cancer (Carethers, 2008). In stage III cancer may have spread 
through the mucosa of the colon wall to the submucosa and muscle layer, and has spread to nearby 
lymph nodes or tissues near the lymph nodes. In stage IV cancer has spread through the blood and 
lymph nodes to other parts of the body, such as the lung, liver, abdominal wall, or ovary (Winslow, 
2014). For this last stage, specific growth factor inhibitors, such as bevacizumab [antibody against 
VEGF] and cetuximab [antibody against EGFR] can also be added to the 5-FU-based chemotherapy. 
All of these treatments have diverse side effects and some of them are only for palliative care 
(Carethers, 2008). 
38 
 
As said before, new antitumour therapies are needed, including novel combinations with 
established chemotherapeutics. For this purpose is important to study drug combinations and 
administration schedules with more efficacies and less side-effects. In addition, the complexity of 
cancer and drug resistance requires a treatment that is able to target more than one biological 
component (Yap et al., 2013). 
Some authors propose that the metal rhenium is more suitable for the treatment of cancer 
patients with anemia than iron (Collery et al., 2004). Rhenium, besides its possible antitumor potential, 
stabilizes the erythrocyte membrane by an antioxidant effect, protecting the erythrocytes against toxic 
agents that induce hemolysis (Shtemenko et al., 2002). In this way, rhenium could be used in 
combination with other cytotoxic drugs, like cisplatin, in order to reduce side effects and improve the 
antitumour potencial (Collery et al., 2014). As stated before the use of HMT, the ligand of the 
compound 2, as an adjuvant to radiation and cisplatin in the treatment of the solid tumours with 
promising results was reported (Masunaga et al., 2010). 
These observations potentiated to test the effect on HCT116 cell viability of the combined 
therapy with compound 2 and cisplatin (Figure 3.10 and Figure 3.11).  Besides the 48-hour treatment 
with cisplatin (IC50) or compound 2 (IC50) alone, the simultaneous administration of both compounds 
was analysed as well as the administration of cisplatin for 24h and then the administration of 
compound 2  for more 24h, and vice versa (Figure 3.10 and Figure 3.11).  
 
 
Figure 3.10 Cell viability in HCT116 cell line after combined therapy with compound 2 and cisplatin in the 
following conditions (A) to (E): (A) 15.3 µM of cisplatin for 48h, (B) 86.5 µM of compound 2 for 48h, (C) 15.3 µM of 
cisplatin for 24 hours and afterwards 86.5 µM of compound 2 for more 24h and (D) vice versa, and the (E) 
simultaneous addition of cisplatin (15.3 µM) and compound 2 (86.5 µM) for 48h. Cell viability was assessed by 
MTS assay. The values shown correspond to the media of three independent assays. The error bars correspond 
to the standard error of the mean (p>0.05, t-test). Cell viability values were normalized to the control cells 
(presence of DMSO 0.1%). 
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Figure 3.11 Cell viability in HCT116 cell line after combined therapy with compound 2 and cisplatin in the 
following conditions (A) to (E): (A) 15.3 µM of cisplatin for 48h, (B) 95 µM of compound 2 for 48h, (C) 15.3 µM of 
cisplatin and afterwards 95 µM of compound 2 for more 24h and (D) vice versa, and the (E) simultaneous addition 
of cisplatin (15.3 µM) and compound 2 (95 µM) for 48h. Cell viability was assessed by MTS assay. The values 
shown correspond to media of three independent assays. The error bars correspond to the standard error of the 
mean (p>0.05, t-test). Cell viability values were normalized to the control: (presence of DMSO 0.1%). 
The best results were for the combined therapeutics where was administered cisplatin (15.3 
µM) and then the compound 2 (+/-95 µM) for more 24 hours. 
Ono and co-workers studied the administration in vivo of doxorubicin encapsulated into 
pegylated liposomes and the combination with hexamethylenetetramine (HMT), showing promising 
results (Masunaga et al., 2009). For this reason compound 2 was also tested with doxorubicin on the 
colorectal cancer cell line, with the same therapeutic schedule. The results are shown in Figure 3.12 
and Figure 3.13.  
 
Figure 3.12 Cell viability assay in HCT116 cell line after combined therapy (48 hours) with compound 2 in the 
following conditions (A) to (E): (A) 0.42 µM of doxorubicin, (B) 95 µM of compound 2, (C) 0.42 µM of doxorubicin 
and afterwards 95 µM of compound 2 for more 24h and (D) vice versa, and the (E) simultaneous addition of 
doxorubicin (0.42 µM) and compound 2 (95 µM). Cell viability was assessed by MTS assay. The values shown 
correspond to media of three independent assays. The error bars correspond to the standard error of the mean 
(p>0.05, t-test). Cell viability values were normalized to the control: (presence of DMSO 0.1%). 
 
In Figure 3.13 the best combination of compound 2 and doxorubicin is analyzed in order to 
reduce the administred concentration of doxorubicin, and consequently reducing its side-effects. The 
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best results were observed for compound 2 administration and 24 hours later doxorubicin treatment, 
and vice versa, with a reduction of ~1.5x in the percentage of cell viability compared to doxorubicin 
alone.  
 
Figure 3.13 Cell viability in HCT116 cell line after combined therapy with compound 2 and doxorubicin in the 
following conditions (A) to (H): (A) 95 µM of compound 2 and then 0.25 µM of doxorubicin for more 24h, (B) 95 
µM of compound 2 and then later 0.3 µM of doxorubicin for more 24h, (C) 95 µM of compound 2 and then 0.35 
µM of doxorubicin for more 24h, (D) 95 µM of compound 2 and then 0.42 µM of doxorubicin for more 24h, (E) 
0.25 µM of doxorubicin and then 95 µM of compound 2 for more 24h, (F) 0.3 µM of doxorubicin and then 95 µM of 
compound 2 for more 24h, (G) 0.35 µM of doxorubicin and 24 hours then 95 µM of compound 2 for more 24h,  
and (H) doxorubicin (0.42 µM) and then compound 2 (95 µM) for more 24h. Cell viability was assessed using the 
MTS assay. The values shown correspond to the media of three independent assays. The error bars correspond 
to the standard error of the mean (p>0.05, t-test). Cell viability values were normalized to control cells (presence 
of DMSO, 0.1%). 
  
3.1.2 Compound 4  
In Figure 3.14 the antiproliferative potential of compound 4 in colonrectal carcinoma cell line 
was assessed after 48-hour of treatment. As we can observe there is a high loss of cell viability in the 
presence of this compound being the relative IC50 0.2654 µM. 
When compared to the relative IC50 of doxorubicin (0.42 µM) or cisplatin (15.3 µM) in this 
tumor cell line (Silva, 2012) this result is very promising. In order to understand if this result is due to 
the effect of the compound or the ligand trimeric polythiophene acetic acid (PTAA) we also have 
assessed the antiproliferative potential of the ligand in this cell line (Figure 3.15). It was obtained a 
relative IC50 of 0.6334 µM for the ligand tPTAA that is higher than the compound 4. This might indicate 
that the metallic center is also important for its antitumour properties. 
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Figure 3.14 Cell viability in HCT116 cells after 48 hours of treatment with compound 4. Cell viability was 
assessed using the MTS assay. The values shown correspond to the media of three independent assays for the 
compound. The error bars correspond to the standard error of the mean (*p<0.01 in relation to 0.1 and 0.2 µM of 
compound 4). Cell viability values were normalized to the control cells (presence of DMSO 0.1%). 
 
Figure 3.15 Cell viability assay in HCT116 cell line after 48 hours of treatment only with the tPTAA ligand of 
compound 4. Cell viability was assessed by MTS assay. The values shown correspond to media of three 
independent assays, excepting for 0.5, 0.75 and 500 µM. The error bars correspond to the standard error of the 
mean (*p<0.05 in relation to 0.1 µM of compound 4). Cell viability values were normalized to the control: (no 
added compounds; presence of DMSO 0.1%). Data provided by Master Joana Filipa Pires Silva. 
 
Few communications that use trimeric PTAA have been reported. It is used mainly to identify 
and characterize amyloid deposits (Nilsson et al., 2010). The heterodisperse polythiophene acetic acid 
derivatives, polythiophene acetic acid (PTAA) and trimeric PTAA, emitted yellow-red fluorescence on 
binding to amyloid deposits, being luminescent-conjugated thiophene polymers spectroscopy a 
sensitive and powerful tool for identifying and characterizing amyloid deposits (Heilbronner et al., 
2013; Nilsson et al., 2010). 
Combined therapy of compound 4 and doxorubicin or cisplatin have also been performed due 
to the high antiproliferative potential of this compound in HCT116 tumor cell line (Figure 3.16 and 
Figure 3.17). The best results were observed for the simultaneous administration of 4 and cisplatin 
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(see Figure 3.17) with a reduction of almost 3x in the percentage of cell viability compared to cisplatin 
alone (E bar compared to A bar in Figure 3.16).  
 
Figure 3.16 Cell viability in HCT116 cell line after combined therapy with compound 4 and doxorubicin in the 
following conditions (A) to (E): (A) 0.42 µM of doxorubicin for 48h, (B) 0.2 µM of compound 4 for 48h, (C) 0.42 µM 
of doxorubicin and afterwards 0.2 µM of compound 4 for more 24h and (D) vice versa, and the (E) simultaneous 
addition of doxorubicin (0.42 µM) and compound 4 (0.2 µM) for 48h. Cell viability was assessed using the MTS 
assay. The values shown correspond to media of three independent assays. The error bars correspond to the 
standard error of the mean (p>0.05, t-test). Cell viability values were normalized to the control cells (presence of 
DMSO 0.1%). 
 
Figure 3.17 Cell viability assay in HCT116 cell line after combined therapeutics with compound 4 in the following 
conditions (A) to (E): (A) 15.3 µM of cisplatin, (B) 0.2 µM of compound 4, (C) 15.3 µM of cisplatin and afterwards 
0.2 µM of compound 4 for more 24h and (D) vice versa, and the (E) simultaneous addition of cisplatin (15.3 µM) 
and compound 4 (0.2 µM). Cell viability is assessed by MTS assay. The values shown correspond to media of 
three independent assays. The error bars correspond to the standard error of the mean (p> 0.05, t-test). Cell 
viability values are normalized in relation to the control cells: (presence of DMSO 0.1%). 
 
When tested in fibroblasts, compound 4 also promotes a high loss of cell viability (Figure 
3.18). For this reason, it would be interesting to study compound 4 in a liposomal drug delivery system 
(Fernandes and Baptista, 2013). 
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Figure 3.18 Cell viability in HCT116 cells after 48 hours of treatment with compound 4. Cell viability was 
assessed using the MTS assay. Cell viability values were normalized to the control cells (presence of DMSO 
0.1%). Data provided by Master Joana Filipa Pires Silva. 
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3.2 Laser Flash photolysis 
 
The Laser Flash photolysis studies were performed due to the possibility of formation of 
transient species by the rhenium compounds. This line of thinking was based on studies from Kastl 
and co-workers concerning the derivatives of a nontoxic luminescent probe of rhenium applied for 
biological imaging that was discovered to have antitumor properties when irradiated at a suitable 
wavelength (Kastl et al., 2013). Photochemical activation also permits to achieve precise spatial and 
temporal control of the biological action of transition-metal complexes that behave as inactive 
“prodrugs” in the absence of light. In this way, transition-metal complexes could be used for the light-
induced liberation of bioactive compounds from the metal coordination sphere as well as as to induce 
a direct action of the metal center (Schatzschneider et al., 2010). 
Flash photolysis is a commonly used fast reaction technique for photochemical reactions. The 
flash photolysis concept is very simple: a short pulse of light is used to interact with a sample that has 
been placed in the optical path of a spectrometer. The result of this interaction can be either a 
transient absorption or an emission process.  The laser pulse contributes to the depletion of the 
ground state of the compound, and the detector will measure the number of counts, at the prescribed 
wavelength, with respect to time. The counts will decrease following a negative exponential law that 
can be characterized by a decay time τ.  
When detecting the absorbance at the absorption wavelength corresponding to S0 --> S1, the 
flash creates a negative ΔOD due to the depletion of ground states, which will then decay towards 0 
(equilibrium state). This decay corresponds to fluorescence and internal conversion phenomena, and 
it is consequently very fast. However, if the molecule studied has the capability to do intersystem 
crossing, some of the excited singlets will become triplets which will then decay (3T1 --> 1S0) by 
phosphorescence, delayed fluorescence, and internal conversion, which are all slow phenomena. This 
can give the quantum yield of triplet formation by comparing the ΔOD that is recovered directly after 
the flash (mostly due to fluorescence and internal conversion) and the ΔOD slowly recovered (and 
thus assigned to triplet states coming back to ground state). 
The objective of the experiments was the determination of the quantum yield of triplet 
formation for compound 2, and if it can originate transient species. For that purpose the transient 
absorption spectra for compound 2 in water and methanol were acquired. Two solvents of different 
polarity were used because is it known that the photochemical behavior is influenced by environment. 
The results are shown in Figure 3.19. The possibility of transient species formation in water (600 nm) 
was less clear in methanol. 
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Afterwards, an energy-transfer experiment was performed. This experiment consists in 
exciting another reference molecule that has the ability to transfer the energy from its T1 excited states 
to the T1 states of an acceptor molecule. This was accomplished by comparing the decays of pure 
donor molecule and a mixture of donor molecule and acceptor, which could gave the information 
on donor-to-acceptor energy transfer rate constant (ket) and consequently on the concentration of 
triplets in compound 2.  Several criteria are necessary to have a good donor molecule: ET (energy gap 
between T1 and S0) of the donor should be bigger than the ET of the acceptor; the donor should have a 
quantum yield of triplet formation close to 1; the donor molecule should be soluble in water, what was 
more difficult because most of the photochemistry studies available in the reference book were 
conducted in organic solvents; the donor must have a singlet excitation energy corresponding to one 
of the laser frequency available; there must be a spectral region where the triplet of the acceptor 
absorb, but not those from the donor, otherwise the quenching effect may not be observed to its full 
scale.  
The energy value corresponding to the highest energy peak observed in the 77K emission 
spectrum of compound 2 in methanol was measured previously. The highest energy peak 
Figure 3.19 Transient absorption spectra of compound 2 in water (above) and in methanol (bottom). Laser Flash 
Photolysis experiments were carried out at room temperature. The concentrations of compound 2 were adjusted 
to yield an absorbance of 0.2 at the excitation wavelength (266 nm, laser enery around 10 J).The distilled water 
solution was deaerated for at least 5 minutes with oxygen-free nitrogen. Filters were placed in the light path to 
narrow the spectrum and remove wavelengths inferior to 305 nm. Transient absorption spectra were recorded 
after the laser pulse (ten shots at each wavelength, with an interval of ten nanometers).  
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corresponds to the transition T1 --> S0 of the first vibrational states. Following these criteria, it was 
chosen benzophenone (see Table 3.2). The results are shown in Figure 3.20. 
 
Table 3.2 The information of the benzophenone solvent for the designing of triplet-triplet energy transfer 
experiments in flash photolysis.  
 λs0-0 ET фT λT ƐT τT 
n/b 379 68.6 1.0 530 7220 6.9 
p/nb 384 69.2 1.0 525 6250 50 
Legend: The triplet energy, ET is given in units of kcal/mol, and the singlet energy is given as an excitation 
wavelength, λs0-0 (nm). The triplet quantum yields, фT, and triplet lifetimes, τT (µs), triplet-triplet absorption 
wavelength, λT , molar absorption coefficient, ƐT (M-1cm-1), at that wavelength. To distinguish aromatic solvents for 
the pair of a given compound from nonaromatic solvents, “b” for “benzene-like” is used for aromatic solvents, and 
“nb” is used for other solvents. One or the other of these two symbols follow the “/” in the solvent column and refer 
only to the (λT, ƐT) column. The symbol preceding the “/” in the solvent column is a nonpolar/polar classification for 
the four properties, λs0-0, ET, фT and τT. Adapted from Murov et al., 1993. 
 
 
Figure 3.20 Transient absorption spectrum of benzophenone in water after the addition of compound 2 (2.6x10-4 
M). The volumes added during the titulation of benzophenone (10-5 mol/L) with compound 2 are described in the 
Table 2.3. Laser Flash Photolysis experiments were carried out at room temperature at the excitation wavelength 
of 266 nm and laser enery around 10 J. Filters were placed in the light path to narrow the spectrum and remove 
wavelengths inferior to 305 nm. 
 
The time-resolved spectrum of benzophenone in water after the addition of compound 2 is the 
same of the benzophenone alone. No significative quenching effect was observed after the addition of 
compound 2 and the possibility of transient species formation was discarded. It could be said that the 
formation of transient species seen for compound 2 in water was due to solvated electrons in water as 
seen by other authors (Urbanek, J., 2014; Abel et al., 2012; Chen et al., 2012). 
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DNA interaction assays 
 
3.3 Study of the interaction between compounds and pUC 18 plasmid DNA 
DNA unwinding properties of compounds 2 and 4 were further explored by electrophoretic 
mobility shift assay (EMSA) using pUC18 plasmid DNA.  
Covalently closed circular DNA can assume different degrees of supercoiling ranging from the 
fully relaxed form to the fully supercoiled isoform. These isoforms can be separated as discrete bands 
using gel electrophoresis allowing the direct assessment of single or double strand breaks due to the 
presence of the compounds or the indirect determination of compound intercalation. 
For the extracted plasmid a ratio Abs260/Abs280 of 1.84 and a value Abs260/Abs230 of 1.79 were 
obtained. The results of EMSA are shown in Figures 3.21 and 3.22. For compound 4, the relative 
percentages of plasmid DNA were not calculated because it was not possible to see all plasmid DNA 
isoforms. However, the results are very similar to compound 2. It can not be seen a decrease in the 
mobility of supercoiled DNA upon incubation with compound 2 and 4. In addition, the mobility of 
relaxed DNA (circular) for compound 2 is not alterated, eliminating the possibility of condensation of 
DNA helix due to DNA diadducts formed by the metal complexes. No perturbations of terciary 
structure of supercoiled DNA can be seen. The coalescence point for the two compounds at the range 
of concentrations tested, corresponding to the amount of intercalator molecules needed for complete 
removal of all supercoils from DNA (Palchaudhuri and Hergenrother, 2007), can not be determined. 
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Figure 3.21 EMSA of 200 ng of pUC18 plasmid DNA after being exposed to compound 2 during 24 hours at 37ºC 
(left) and relative percentages of plasmid DNA isoforms per lane (3 independent assays). From left to the right on 
the first image: Marker is the DNA size marker λ DNA/HindIII, the concentrations (µM) of compound 2 used are 0, 
10, 30, 60, 80, 100 and 150 µM, DMSO is the vehicular control lane with the DMSO volume corresponding to the 
maximum volume of compound 2 added, and the last lane is pUC18 linearized by EcoRI enzyme. 
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Figure 3.22 EMSA of 200 ng of pUC 18 after being exposed to the compound 4 during 24 hours at 37ºC. From 
left to the right: Marker is the DNA size marker λ DNA/HindIII, the concentrations (µM) of compound 4 used are 0, 
10, 30, 60, 80, 100, 150 and 200 µM, DMSO is the vehicular control lane with the DMSO volume corresponding to 
the maximum volume of compound 4 added, and the last lane is pUC18 linearized by EcoRI enzyme. 
 
3.4 DNA binding assays 
DNA binding studies are important because many anticancer agents perform their action 
through binding to DNA leading to DNA damage in cancer cells, interrupting replication and 
transcription processes, and inducing apoptosis.  
Generally, DNA-acting anticancer drugs can be classified into three categories:  1) drugs that 
form covalent linkages with DNA; 2) drugs that form noncovalent complexes with DNA by either 
intercalation or groove-binding and 3) drugs that cause DNA backbone cleavages (Hajian et al., 2009). 
Rhenium is a metal able to induce adducts with nucleosides, like cisplatin, with cytotoxic 
properties on malignant cells (Collery et al., 2014). Re can bind to DNA adenine through the N1, N6 
positions, or to guanine through the N7 position. Re can also induce Re-nucleotide adducts less stable 
than with cisplatin (Zobi et al., 2007).  
To assess the type of interaction of the Re compound 2, spectrophotometric studies with ct-
DNA were done. The ratios Abs260/Abs280 and Abs260/Abs230 obtained for ct-DNA were 1.88 and 2.22, 
respectively.  
The binding constant was calculated (see Table 3.3) and the absorption spectrum after 24-
hour incubation at 37ºC is shown in Figure 3.23. 
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Table 3.3 Spectrophotometric assays of the interaction of compound 2 with calf-thymus DNA (ct-DNA). The data 
is represented as [DNA] x εa x εf versus [DNA] and then the ratio of the slope, 1/(εb-εf),  to the intercept, 1/Kb(εb-
εf) gives the binding constant, Kb, represented as Kb +/- SEM. 
Assay number Binding constant (Kb, M-1) Mean (M-1) 
1 4.16x105 
 
 
5.01 (+/- 1.12) x105 
 
2 3.64x105 
 3 7.23x105 
 Legend: εa is the apparent molar extiction coefficient, εf is the molar extiction coefficient of the compound and εb 
is the molar extinction coefficient of the complex bounded to DNA. 
The UV-Visible spectrum of compound 2 with ct-DNA exhibits two major band at 235 nm and 
260 nm. Compounds binding with DNA through intercalation usually results in hypochromism and 
bathochromism (Sirajuddin et al., 2013). It can not be seen neither a hypsochromic or bathochromic 
shifts. However, a hypochromic effect exists. Additionally, based on the absorbance values obtained in 
the spectroscopic titration, the value obtained for Kb was 5.01 (+/- 1.12)×105M−1. Kb value is lower 
than those observed for typical classical intercalators, e.g. Kb for ethidium bromide–DNA complex is 
equal to 7×107 M–1 (Ahmadi et al., 2011). Therefore, in addition to the results of the 
electrophoretogram (see Figure 3.21) it could be proposed that compound 2 interacts weakly with ct-
DNA and has a non-covalent mode of binding. Furthermore, the low binding constant ~105 suggests 
that the interaction between the metal complex and DNA might not be intercalative in nature. More 
studies are needed in order to support the results, such as fluorescence measurements, viscosity 
measurements or even melting studies.  
 
Figure 3.23 Absorption spectra of compound 2 (200 µM) with a range of ct-DNA concentrations from 1 to 10 (2.84 
µM to 80.42 µM). 
Despite our results, other authors have synthesized and characterized tricarbonyl rhenium 
complexes with intercalative binding behaviour (Olmon et al., 2011). Indeed, Ma and co-workers 
studied Re(CO)3(2-appt)-Cl [2-appt is 2-amino-4-phenylamino-6-(2-pyridyl)-1,3,5-triazine], a rhenium 
complex that can participate in both hydrogen-bonding and π-π interactions. Results from 
spectroscopic titrations and viscosity showed a low binding constant (~104) and indicated that this 
metal complex interacts with DNA via groove binding (Ma et al., 2007).  
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While compound 2 with the hexamethylenetetramine (HMT) ligand does not present a strong  
interaction with DNA, some studies show that if this ligand alone is coadministrated with doxorubicin, it 
can potenciate its ability to interact with DNA. HMT is known to hydrolyze and release up to six 
molecules of formaldehyde in a pH-dependent manner. The capability of doxorubicin to form 
interstrand lesions in the absence or presence of formaldehyde releasing agent HMT was analysed by 
Swift and co-workers using gel electrophoresis. Doxorubicin in the absence of formaldehyde formed 
no interstrand lesions whereas doxorubicin in the presence of HMT readily formed interstrand lesions 
in a pH-dependent manner and the amount of these lesions increased with decreasing pH. In addition, 
doxorubicin-DNA interstrand lesions have been shown to be considerably more effective in triggering 
apoptosis and to be more cytotoxic than doxorubicin alone (Swift et al., 2003). It would be interesting 
to study the simultaneous incubation of doxorubicin and the compound 2 with DNA to see the Re 
metal influence. 
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3.5 Human Serum Albumin interaction assays 
 
The main biological effect of Re is considered to be the formation of adducts with proteins or 
with DNA. The formation of stable covalent adducts with proteins was shown with lysozyme, with the 
binding of Re to His15 via the replacement of one coordinated water molecule, and confirmed by X-ray 
crystallography (Collery et al., 2014). The hypothesis of adducts formation with the DNA was not 
proven for the Re compound 2 (see Sections 3.3 and 3.4).  
The interaction of compound 2 with Human Serum Albumin (HSA) was studied by 
fluorescence spectroscopy. HSA is a 66 kDa protein commonly present at concentrations of around 
600 µM in human plasma. The formation of a complex between a drug and HSA decreases the 
concentration of unbound molecules in the plasma and thereby affects the drug’s action. From the 
pharmacokinetic point of view, binding to albumin is beneficial only as it extends the length of time at 
which the free drug remains above its therapeutically efficacy concentration. For this reason, it is 
important to know the affinity of any drug for albumin (Buttar et al., 2010). 
Spectrofluorimetry can provide precise information about protein-drug interactions. A diverse 
range of process can result in fluorescence quenching, including complex formation.  The quenching 
produced by a quencher to a fluorescent molecule results from the collisional encounters between the 
fluorophore and the quencher, which is called collisional or dynamic quenching. Static quenching is 
due to complex formation (Montero et al., 1994). 
One of the major problems with this technique is the inner-filter effect that is the absorption of 
light at both the excitation and emission wavelengths (Larsson et al., 2007). However, as is observed 
in Figure 3.24, this is not a problem to have into consideration. There is no sobreposition between the 
absorption band of compound 2 and the emission band of HSA when excited at 295 nm. 
 
Figure 3.24 Fluorescence spectrum of HSA (1.5x10-5M) on the right and absorption spectrum of compound 2 on 
the left (200 µM). The excitation wavelength used was 295 nm. 
In Figure 3.25 the fluorescence spectrum of HSA and compound 2 is shown. We can observe 
the quenching of HSA with increasing concentrations of compound 2 (Figure 3.25).  
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Figure 3.25 Fluorescence spectrum of HSA (1.5x10-5M) with compound 2 from 1 to 10 (only HSA and 7.2x10-6M 
to 1.3x10-3M of compound 2 with HSA). The excitation wavelength was 295 nm. 
Fluorescence quenching data was analyzed to obtain various binding parameters for the 
interaction of compound 2 and HSA. Quenching data were first analyzed using the Stern-Volmer 
equation F0/F = 1 + K [compound 2 concentration], being F the fluorescence of protein solution in 
presence of compound 2, and K is the Stern-Volmer constant. Fluorescence of the protein sample that 
contained only HSA in phosphate buffer is taken as 100% fluorescence (F0), while the phosphate 
buffer gave the 0% fluorescence. 
Plotting F0/F versus [compound 2 concentration] two types of plots may be obtained. A linear 
Stern-Volmer plot indicates that only one type of quenching, dynamic, occurs. When the same 
fluorophore can be quenched both for collisions and by complex formation, an upward curvature is 
observed (Montero et al., 1994). In Figure 3.26 can be seen a linear Stern-Volmer plot, and the Stern-
Volmer constant is calculated in Table 3.4. 
 
Figure 3.26 Stern-Volmer plot obtained from the titration of 1.5x10-5M of HSA with compound 2. 
Table 3.4 Stern-Volmer constant for compound 2, represent as K +/- SEM. 
 First assay Second assay Third assay Mean 
Stern-Volmer constant (M-1) 802.94 909.06 863.96 858.65 +/- 30.75 
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From the relative fluorescence values the fraction of the fluorescence that has been 
quenched, Q, is obtained as Q = (F0 - F)/100. With this parameter a new representation of Q versus 
[compound 2 concentration]/[HSA concentration] could be made (Montero et al., 1994). However, the 
limit quenching concentration can not be determined, since the maximal quenching was not achieved 
with the range of concentrations tested for compound 2. The reciprocal of fractional quenching versus 
the reciprocal of the free ligand concentration plot gave an average value of binding constant of the 
protein-quencher complex (Kd) of 3.10 (+/- 1.2) x 103 M-1. 
 
Table 3.5 HSA binding constant for compound 2, represent as Kd +/- SEM. 
 First assay Second assay Third assay Mean 
Binding constant (M−1) 1.97x103 1.87x103 5.44x103 3.10 (+/- 1.2) x 103 
 
It is shown that there was a relatively moderate interaction between compound 2 and HSA. 
The binding constant was reported to be 1.1 (±0.3)×104 M−1 (Agudelo et al., 2012) for doxorubicin to 
HSA by fluorescence methods and for Uracil, 5-Fluorouracil and 5-Chlorouracil was suggested a static 
quenching mechanism with a binding constant of ∼104 M−1  at 303 K that was considered in the range 
suitable for drug transportation (Bakkialakshmi et al., 2012). 5-Fluorouracil is one of the most used 
drug for the treatment of advanced colorectal cancer (Carethers, 2008). 
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3.6 Proteomic analysis  
In order to identify the potencial biological targets of compound 2, the proteome of HCT116 
cells exposed or not to the compound (IC50) after 48 h was performed. Protein extracts were subjected 
to 2-DE electrophoresis, obtaining a total of 4 bidimensional gels, corresponding to the proteome 
duplicates in the presence or absence (0.1 % DMSO) of the compound.  
2-DE electrophoresis is suitable for proteome analysis and it allows detecting large quantity of 
proteins in a single run. Notwithstanding, it is not suitable for low abundant proteins, affected by 
posttranslational modifications (Wang and Chiu, 2008).  
Data analysis was carried out in three distinct stages. First, the capture of digitised gel images 
which provides quantitative data in the form of density maps. There is a linear correlation between the 
amount of protein in the gel and the amount of stain bound. To overcome gel-to-gel variation in 
staining intensity, the data have to be normalized, expressing each spot relative to the total image 
intensity of the gel. Then, a spreadsheet of matched spot data is created and the spots labeled. 
Quantitative analysis of the variation of abundance of protein spots was performed using Melanie 7.0 
software. Protein identification was done by gel-by-gel comparison comparison between a reference 
gel with protein spots previously identified at the laboratory. The results are represented in Figure 
3.27.  
 
 
Figure 3.27 Image of the 2-DE gels of HCT116 cell line treated during 48 hours with 0.1% of DMSO (left) and 
86.5 µM of compound 2 (right), stained with comassie blue R350. The marked spots correspond to the identified 
proteins with the respective landmark and abbreviation of the name. Gels are representatives from duplicate 
experiments. 
From the 2-DE gels we were able to detect 34 spots (proteins and relative abundance): 
Endoplasmin (ENPL, 0.7), Tubulin alpha-1B chain (TBA1B, 0.6), Ran-specific GTPase-activating 
protein (RANG, 0.4), Heat shock cognate 71 kDa protein (HSP7C, 0.5), Bifunctional purine 
biosynthesis protein (PUR9, 0.67), T-complex protein 1 subunit gamma (TCPG, 0.67), Ezrin (EZRI, 
1.7), 40S ribosomal protein SA (RSSA, 1.5), Actin Gamma 1 (ACTG, 0.8), chaperones such as 
HSP90B (0.96), HSP71 (0.9), TCPA (1.13), TCPB (0.98) , GRP75 (1.31), Small glutamine-rich 
tetratricopeptide repeat-containing protein alpha (SGTA, 0.68) prolyl 4-hydroxylase beta polypeptide 
(P4HB, 0.9), Glutamate dehydrogenase (DHE3, 3.3), Proliferation-associated protein 2G4 (PA2G4, 
2.2), Proteasome activator subunit 1 (PMSE1, 1.3), Annexin A2 (ANXA2, 2.03), Eukaryotic initiation 
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factor 4A-II (IF4A2, 2.9), Stress-induced-phosphoprotein 1 (STIP1, 0.18), 14-3-3 protein zeta (1433z, 
0.97), Calreticulin (CALR, 1.3), the mitochondrial Complement 1q-binding protein (C1qbp, 0.3), Protein 
disulfide isomerase family A member 3 (PDIA3, 1.3), Cytosol aminopeptidase (AMPL, 0.8) and Alpha-
enolase protein (ENOA, 1.3). 
It was considered biologically significant the relative abundance (compared to control) higher 
than 1.5 or smaller than 0.7 (reference). In this way, 15 known spots showed biologically significant 
relative abundance, and were previously identified in the laboratory by mass spectrometry (Table 3.6). 
From the identified spots, differences in protein abundace spots were not statistically significant (t-test, 
p <0.05 was considered significant). This is due to insufficient number of replicates, which give a 
better estimation of variability. This variability come from the biological and technical phases (Chich et 
al., 2007; Wood et al., 2004).  
It may be inferred that compound 2 interferes with proteins responsible for the maintenance of 
the cytoskeleton (Table 3.6), such as Tubulin alpha-1B chain (TBA1B), Ezrin (EZRI) and T-complex 
protein 1 subunit gamma (TCPG). For some of them there is a link with apoptosis. 
 
Table 3.6 Proteins whose expression was significantly changed relatively to the control (more than 1.5-fold or less 
than 0.7-fold) in HCT116 cells exposed to 86.5 µM of compound 2. Proteins responsible for the maintenance of 
the cytoskeleton. 
Landmark Number  
and Protein Name 
Relative 
abundance 
Function 
(71)Tubulin alpha-1B chain 
(TBA1B) 
0.6 Tubulin is the major constituent of microtubules. It binds 
two moles of GTP. 
 
(143)T-complex protein 1 subunit 
gamma (TCPG) 
0.67 Molecular chaperone; assists the folding of proteins 
upon ATP hydrolysis. Known to play a role, in vitro, in 
the folding of actin and tubulin. 
 
(56)Ezrin (EZRI) 1.7 Probably involved in connections of major cytoskeletal 
structures to the plasma membrane.  
 
Legend: adapted from: 
(71)http://www.uniprot.org/uniprot/P68363;(143)http://www.uniprot.org/uniprot/P49368;(56)http://www.uniprot.org/
uniprot/P15311. 
 
TBA1B, which was less abundant for cells exposed to compound 2, is the main component of 
the microtubules. As microtubules are highly involved in cellular growth, they are a potential target for 
cancer treatment. Some antimitotic agents inhibit cell proliferation by binding to microtubules and 
suppressing microtubule dynamics during the mitotic stage of the cell cycle (Dumontet and Jordan, 
2010). Other advantage of this kind of compounds is that binding to tubulin and in this manner 
perturbing the microtubule stability and the function of the spindle apparatus, causes cancer cells to 
arrest and undergo apoptosis. Several microtubule inhibitors are in clinical trials (Aryapour et al., 
2012).   
Ezrin was more abundant for cell exposed to compound 2. EZRI is involved in the adhesion and 
organization of the cellular structure. Ezrin acts as a linker between the plasma membrane and the 
actin cytoskeleton and plays important roles in cell motility, invasion and metastasis (Leiphrakpam et 
al., 2014). Recently, Ezrin has been linked to Akt-mediated cell survival. It was reported that Akt2 
phosphorylates Ezrin to activate it and phosphorylates X-linked inhibitor of apoptosis protein (XIAP) for 
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reducing its degradation conferring resistance to caspase activation and apoptosis. Transient 
knockdown using ezrin siRNA in colorectal cancer cells led to the downregulation of XIAP, which is 
critical for cell survival and tumor growth and for supporting the metastatic process in vivo. Ezrin 
knockdown also resulted in approximately 1.5 fold increase in cell death in colorectal cancer cells 
(Leiphrakpam et al., 2014).  
T-complex protein 1 subunit gamma is a subunit in a large molecular chaperone known as 
chaperonin-containing tail-less complex polypeptide-1, which maintains cellular protein folding 
homeostasis by assisting the biogenesis of many proteins, including the fold of actin and tubulin, and 
non-cytoskeletal substrate proteins, including cyclin E, CDC20 and the Von Hippel-Lindau tumor 
suppressor (Lee et al., 2012). TCPG was less abundant in cells treated with compound 2 and this 
might be related to less abundance of TBA1B, the main component of microtubules. 
In addition, increased expression of cytosolic chaperonin-containing t-complex polypeptide 1 in 
human colon carcinoma has been reported (Shi et al., 2013). Lee and collaborators demonstrate by 
proteomic analysis that p53 loss in HCT116 colon cancer cells is associated with up-regulation of a 
phosphorylated TCPG variant. However, there is no direct evidence that TCPG plays a role in p53-
regulated biological functions such as apoptosis, senescence and/or cell cycle regulation (Lee et al., 
2012). The p53 plays an important role in the response to genotoxic stress and hypoxia (Vogelstein et 
al., 2000). In this way, TCPG abundance in cells exposed to compound 2 could also be related to p53 
activity. 
There are also alterations in the abundance of proteins related to cellular protection (Table 3.7) 
caused by compound 2, such as GRP94, ANXA2, HSP7C and related proteins. 
 
Table 3.7 Proteins whose expression was significantly changed relatively to the control (more than 1.5-fold or less 
than 0.7-fold) in HCT116 cells exposed to 86.5 µM of compound 2. Proteins related to cellular protection. 
Landmark Number  
and Protein Name 
Relative 
abundance 
Function 
(52)Endoplasmin (ENPL/ GRP94) 0.7 Molecular chaperone. Functions in endoplasmic 
reticulum associated degradation (ERAD). Has ATPase 
activity. 
 
(176)Small glutamine-rich 
tetratricopeptide repeat-containing 
protein alpha (SGTA) 
 
 
0.68 
Co-chaperone that binds directly to HSC70 and HSP70 
and regulates their ATPase activity. 
(120)Stress-induced-
phosphoprotein 1 (STIP1) 
 
0.18 Mediates the association of the molecular chaperones 
HSC70 and HSP90. 
(7)Heat shock cognate 71 kDa 
protein (HSP7C) 
 
0.5 Acts as a repressor of transcriptional activation. May 
have a scaffolding role in the spliceosome assembly as 
it contacts all other components of the core complex.  
 
(175) Annexin A2 (ANXA2) 
 
2.0 May be involved in heat-stress response. 
Legend: adapted from: 
(52)http://www.uniprot.org/uniprot/P14625;(176)http://www.uniprot.org/uniprot/O43765;(120)http://www.uniprot.or
g/uniprot/P31948;(7)http://www.uniprot.org/uniprot/P11142; (175) http://www.uniprot.org/uniprot/P07355.  
 
The GRP94 or endoplasmin is the most abundant glycoprotein in the endoplasmic reticulum. It 
belongs to the family of the heat-shock proteins, and assists the folding and assembly of a wide range 
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of proteins. The depletion of the chaperone GRP94 makes worms sensitive to cisplatin (Natarajan et 
al., 2013). Authors explain that this could be due to elevated Endoplasmic Reticulum stress levels in 
grp94 mutants. This could be explored to enhance the effects of cisplatin based cancer therapy. The 
expression of this endoplasmin in HCT116 cells treated with compound 2 was smaller than 0.7 
compared to the control. However, the combined therapeutics of compound 2 and cisplatin was tested 
(Figure 3.11) without a significant sensitivity of colon cancer cell line to the therapeutic schedule 
chosen. This may be due to the higher levels of Ezrin that regulates cell survival signaling in colorectal 
cancer (Leiphrakpam et al., 2014). 
  The GRP94 also shows ATPase activity and plays an essential role in the cellular protection 
against different stress situations. GRP94 is dramatically up-regulated in colorectal cancer (animal 
models and human tumors), allowing the correct folding of several oncogenic products and a more 
aggressive tumour phenotype, metastasis and a poor evolution of the disease (Romay et al., 2011). 
Small glutamine-rich tetratricopeptide repeat-containing (SGTA) protein alpha was less 
abundant in cells treated with compound 2. SGTA has also a role in Hsp70-mediated folding (Paul et 
al., 2014). Less abundance of SGTA is coherent with less abundance of Stress-induced-
phosphoprotein 1 (STIP1) since it mediates the association of the molecular chaperone HSP7C. Heat 
shock cognate 71 kDa protein (HSP7C) is a constitutively expressed chaperone. The basal level of 
HSP7C in cisplatin-resistant cervix squamous cell carcinoma cells was up-regulated compared to 
cisplatin-sensitive cells, as reported by Castagna and co-workers (Castagna et al., 2004). In this way, 
the less abundance of HSP7C and SGTA caused by compound 2 is favorable to tumour cells death. 
Annexin A2 (ANXA2) is more abundant in cells exposed to compound 2. ANXA2 is reported to 
be highly expressed in human colorectal cancer cell lines including HCT116 (Wang and Lin, 2014; 
Emoto et al., 2001) and is a marker for drug resistance (Wang and Lin, 2014). This could be an 
adaptive response to compound 2. On the other hand, ANXA2 is a cellular redox regulatory protein. It 
possesses a reactive cysteine residue (Cys-8) which is oxidized by H2O2 and subsequently reduced 
by the thioredoxin system, thereby enabling annexin A2 to participate in multiple redox cycles 
(Madureira and Waisman, 2013). Elevated levels of ANXA2 could mean that compound 2 induces 
oxidative stress in HCT116 cells, however the level of several heat shock proteins and other proteins 
involved in cellular protection didn’t corroborate this possibility. 
Other proteins affected by compound 2 are related to DNA synthesis, translation and other 
cellular functions (Table 3.8). 
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Table 3.8 Proteins whose expression was significantly changed relatively to the control (more than 1.5-fold or less 
than 0.7-fold) in HCT116 cells exposed to 86.5 µM of compound 2. 
Landmark Number  
and Protein Name 
Relative 
abundance 
Function 
(38)Ran-specific GTPase-activating 
protein (RANG) 
0.4 Inhibits GTP exchange on Ran. May act in an 
intracellular signaling pathway which may control the 
progression through the cell cycle. 
 
(79)Mitochondrial protein C1qbp 0.3 Involved in ribosome biogenesis, regulation of 
apoptosis, transcriptional regulation and pre-mRNA 
splicing. 
 
(63)Bifunctional purine biosynthesis 
protein (PUR9) 
0.67 Bifunctional enzyme that catalyzes 2 steps in purine 
biosynthesis. 
 
(20)40S ribosomal protein SA 
(RSSA) 
1.5 Assembly and/or stability of the 40S ribosomal subunit. 
Cell surface receptor for laminin. May play a role in cell 
fate determination and tissue morphogenesis.  
 
(182)Proliferation-associated 
protein 2G4 (PA2G4) 
 
2.2 Seems be involved in growth regulation. 
(169)Eukaryotic initiation factor 4A-
II (IF4A2) 
2.9 ATP-dependent RNA helicase which is a subunit of the 
eIF4F complex involved in cap recognition and is 
required for mRNA binding to ribosome. 
 
(187)Glutamate dehydrogenase 
(DHE3) 
3.3 Mitochondrial glutamate dehydrogenase that converts 
L-glutamate into alpha-ketoglutarate. 
Legend: adapted from:  
(38)http://www.uniprot.org/uniprot/P43487;(79) 
http://www.uniprot.org/uniprot/Q07021;(63)http://www.uniprot.org/uniprot/P31939;(20)http://www.uniprot.org/unipr
ot/P08865;(182)http://www.uniprot.org/uniprot/Q9UQ80;(169)http://www.uniprot.org/uniprot/Q14240;(187)http://w
ww.uniprot.org/uniprot/P00367. 
 
Bifunctional purine biosynthesis protein was less abundant for cells exposed to compound 2. 
Cancer cells depend mainly on de novo purine pathway for synthesis of adenine and guanine, in 
contrast to normal cells that favor a salvage pathway. In this way, enzymes involved in the de novo 
pathway have become attractive candidates for rational anticancer drug design (Li et al., 2006).  
Complement 1q-binding protein (C1qbp) was less abundant in cells treated with compound 2. It 
is reported to be upregulated in colon cancer cell lines and it contributes to the hyperproliferative, 
hypermigratory and cytoprotected phenotype of a cancer cell line (McGee et al., 2011). 
Proliferation-associated protein 2G4 (PA2G4) was overexpressed in cells exposed to 
compound 2. PA2G4 induces cell cycle arrest possibly by repressing E2A activation of cell cycle 
related genes (Zhang et al., 2003). Compound 2 could trigger cell death by cell cycle arrest. 
Glutamate dehydrogenase (DHE3) and Eukaryotic initiation factor 4A-II (helicase important for 
mRNA translation) were more abundant in cells exposed to compound 2 and these alterations could 
be an adaptive response. Glutamine has an important role in cell growth and energy metabolism. 
Glutamate dehydrogenase (GDH) participates in the second step of glutaminolysis converting 
glutamate to α-ketoglutarate (α-KG). Cancer cells are dependent on glutamine to maintain the 
tricarboxylic acid cycle (TCA) cycle (Zhao et al., 2013).  
A translation-related protein, 40S ribosomal protein SA (RSSA), was up-regulated with 
compound 2 treatment. Downregulation of this protein may be related to the suppression of 
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translation. Moreover, RSSA is also known as a multidrug resistance-associated protein MGr1-Ag, 
and its downregulation can significantly enhance the cytotoxicity of antitumor drugs to cancer cells 
(Yao et al., 2009). 
Ran-specific GTPase-activating protein (RANG) is considered a promising therapeutic target for 
aggressive B-cell lymphoma (Chang et al., 2013). This protein is also less abundant in the proteome 
of HCT116 cells treated with compound 2. Ran is a small GTPase that functions as a molecular switch 
by binding to either GTP or GDP. One essential regulator of this process is Ran-specific GTPase-
activating protein, which also catalyzes the GTP hydrolysis of Ran. It has been found that Ran and 
Ran binding proteins are involved in a broad range of fundamental cellular processes including mitotic 
spindle assembly, cell death, cell proliferation, cell differentiation and malignant transformation. 
Moreover, the abrogation of RANG may lead to cell death (Schreier et al., 2014). This could be one 
inductor of cell death after treatment with compound 2. 
To conclude, after 48h of treatment with compound 2, colorectal cancer cells are more sensitive 
and prone to cell death due to the relative abundance of the heat shock proteins, GRP94 and HSP7C, 
and also RANG protein, a small GTPase involved in many cellular processes. On the other hand, the 
altered abundance of TBA1B protein can consequently alter microtubule stability and the function of 
the spindle apparatus compromised causing cancer cells to arrest and undergo apoptosis. These 
results might be confirmed by detecting the protein levels or activity of downstream caspases, which 
are crucial for apoptosis induction, by western blotting or by enzyme assay, respectively (Sarastea et 
al., 2000). PA2G4 overexpression might indicate that compound 2 triggers cell death by cell cycle 
arrest. In addition, TCPG was less abundant in compound 2 treated cells what might be related to p53 
activity and genotoxic stress response. Ezrin, RSSA and DHE3 were more abundant on colon cancer 
cells treated with the compound 2 that in control, what could be an adaptive response since Ezrin has 
been linked to Akt-mediated cell survival, RSSA with multidrug resistance and DHE3 with cancer cells 
growth. 
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Apoptotic potential assessment 
 
3.7 Hoechst assay 
To visualize nuclear changes and apoptotic body formation that are characteristic of apoptosis, 
HCT116 cells treated for 48h with compound 4 or compound 2 were stained with Hoechst 33285. This 
dye is known to penetrate the plasma membrane and stain DNA in cells without permeabilization 
(Kasibhatla et al., 2006). Cells are observed in a fluorescence microscope and counted in order to 
quantify the level of apoptosis. Cells are scored as apoptotic if their nuclei present chromatin 
condensation and marginalization or nuclear beading. In this assay, apoptotic cells have a stronger 
blue fluorescence compared with nonapoptotic cells.  
Results are shown in Figure 3.28 and Figure 3.29.  
 
 
Vehicle control (0.1%DMSO) 
  
  
 
Figure 3.28 HCT116 cells (0.75 x 105 cells/mL) stained with Hoechst 33258 after treatment with DMSO (0.1% 
DMSO, 48 hours, control). Total magnification of 50x10x. Images are representative of two independent assays. 
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Compound 4 (0.2861 µM) 
  
 
  
 
 
 
Compound 2 (86.5 µM) 
  
 
 
Figure 3.29 HCT116 cells (0.75 x 105 cells/mL) stained with Hoechst 33258 after treatment with compound 4 
(above) and compound 2 (bottom). Total magnification of 50x10x. Images are representative of two independent 
assays. 
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In contrast to control cells, cells treated with the compounds (~IC50) show more nuclear 
condensation and fragmentation (Figures 3.28 and 3.29). Compound 4 seems to be more effective in 
killing tumour cells than compound 2, what corroborates with the results of the cell viability assays. 
However, itseems to be an overestimation of cell death by compound 2 and underestimation by 
compound 4 compared to the cell viability assays. Apparently, apoptosis is not the main mechanism of 
cell death for compound 2 with 4.15 +/-1.16 % of apoptotic cells. However, apoptosis begins several 
hours before the appearance of morphologic features and the morphologic changes usually take place 
in less than 2 hours (Saraste and Pulkki, 2000). 
Although apoptosis is an important mechanism of tumour cells death, a cancer therapy that 
acts solely by inducting apoptosis and had no intrinsic cytotoxicity would cause the death of more 
normal cells than cancer cells. Effective cancer therapies should have a direct toxic activity and inhibit 
vital processes such as DNA replication, microtubule function, and other targets. Some of these 
functions were apparently altered after 48-hour treatment with compound 2 (see Section 3.6). In 
addition, agents that inhibit apoptosis might be useful in conjunction with chemotherapy or 
radiotherapy to reduce dose-limiting side-effects due to apoptosis of normal cells (Gerl and Vaux, 
2005). This may not be the case as some evidences of apoptosis are seen on the Hoeschst images. 
However the proteomic results showed a higher relative abundance for Ezrin after 48-hour treatment 
with compound 2, a protein that when is absent in colorectal cancer cells leads to the downregulation 
of X-linked inhibitor of apoptosis protein (see Section 3.6). This response could be inhibiting apoptosis. 
 
3.8 Flow citometry 
 
Flow citometry was used in this work to assess cell death. The principle of the assay is the 
simultaneous use of two markers, Anexin V in the presence of calcium ions (Brumatti et al., 2008) and 
dye propidium iodide (Brun et al., 2012), which bind to exposed phospholipid phosphatidylserine (PS) 
and DNA, respectively. This technique takes advantage of some earliest morphological changes that 
occur in the plasma membrane during apoptosis such as the translocation of the membrane 
phospholipid phosphatidylserine from the internal layer to the external layer of the cell membrane. To 
distinguish between apoptotic and necrotic cells, the fluorescent dye propidium iodide is used, since it 
can only enter necrotic cells across a damaged plasma membrane (Hingorani et al., 2011).  
Analysis can result in three distinct cellular populations: early apoptotic cells if they are 
positive for Annexin V binding (Annexin V+, PI-), late apoptotic cells are positive for Annexin V and 
propidium iodide binding (Annexin V+, PI+), necrotic cells are negative for Annexin V binding and 
positive for propidium iodide binding (Annexin V-, PI+) and viable cells that are negative for both the 
markers (Annexin V-, PI-) (Hingorani et al., 2011).  
 Results for combined therapy with compound 2 and doxorubicin are in Figure 3.30. 
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Figure 3.30 Evaluation of the apoptotic potential in HCT116 cells. Apoptosis was evaluated and quantified by flow 
cytometry analysis with annexin V-FITC and PI double staining. Cells were treated with 0.1% (v/v) DMSO (vehicle 
control) and (1) the compound 2 at 86.5 µM for 48 h, (2) 0.42 µM of doxorubicin for 48 h, (3) 0.25 µM of 
doxorubicin for 48 h, (4) 0.42 µM of doxorubicin and afterwards compound 2 at 86.5 µM for more 24h and (5) 0.25 
µM of doxorubicin and afterwards compound 2 at 86.5 µM. 
 It is observed 88.2% of viable cells for DMSO (0.1%) control, being the number of apoptotic 
cells (11.1%) higher than necrotic cells (0.7%). This is similar to previous assays in the lab (Silva, 
2012). The results (Figure 3.30) go in line with what is reported for doxorubicin cell death. Doxorubicin 
induces apoptosis via the activation of caspases and disruption of mitochondrial membrane potential 
(Gamen et al., 2000). However, doxorubicin is able to induce cell death by apoptosis only at particular 
dose and treatment conditions and careful consideration of incubation period as well as doxorubicin 
concentrations used is of importance for achievement of apoptosis in treatment of colon cancer cells 
(Lüpertz et al., 2010). Results of combined therapy with either 0.25 or 0.42µM of doxorubicin and 
afterwards 86.5 µM of compound 2 showed a higher number of necrotic cells (55.1%) when used the 
lowest dose of doxorubicin, but a also a higher number of viable cells (2.31%) for the same 
concentration. The same outcome happens when HCT116 cells are exposed to 0.25 µM of 
doxorubicin alone (10.4% of necrotic cells) but the percentage of necrotic cells is higher in combined 
therapy with compound 2 (55.1%). 
The fundamental characteristics of necrosis include cellular energy depletion, damage to 
membrane lipids, and loss of function of homeostatic ion pumps/channels. These events often 
potentiate each other and synergize to cause necrosis (Riccia and Zong, 2006). The proteomic 
analysis of cells exposed to compound 2 showed alterations in proteins related to cell growth and 
energy metabolism. Combined with doxorubicin it can potentiate the alterations of cells exposed to 
doxorubicin and increase the number of necrotic cells as shown in flow citometry. 
Although early apoptosis is virtually seen for cells exposed to doxorubicin alone, when combined 
with compound 2 it increases (0.5% for condition 4 and 0.7% for 5, Figure 3.30). Cell death is not 
significant high in cells exposed to compound 2 (82.5% of viable cells). This could be due to the 
possible adaptive response seen in the proteomic analysis by Ezrin, RSSA and DHE3 overexpression 
on colon cancer cells treated with the compound 2. The percentage of viable cells is also higher than 
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achieved in the MTS assay (~50%). This might mean that its antiproliferactive effect is mainly due to 
cell cycle arrest and not due to apoptosis induction. This hypothesis was also raised in proteomic 
analysis due to PA2G4 overexpression.The results of flow citometry for early (1.4%) and late 
apoptosis (13.3%) of cells exposed to compound 2 are also coherent with the Hoechst staining assay 
in which a low number of apoptotic cells were seen (4.15 +/-1.16 %). 
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4 Conclusions 
 
Cisplatin, oxaliplatin, related metallodrugs as well doxorubicin are extensively used in the 
treatment of a diversity of cancers. However these drugs are highly toxic and tumor becomes drug-
resistance (Holohan et al., 2013). On the other hand, in addition to drug resistance there are also 
complicated side effects (Tacar et al., 2012). New metallic compounds which do not have the same 
mechanism of action of these drugs could fulfil these requirements.  
The in vitro antiproliferative potential of three new rhenium compounds, in particular compounds 1 
and 2 bearing the 1,3,5-triaza-7-phosphaadamantane (PTA) and the hexamethylenetetramine (HMT) 
ligands, respectively, compound 3 bearing the tris(pyrazol-1-yl)methanesulfonate (Tpms) and HMT 
ligands was evaluated using colorectal, chronic myelogenous leukemia, hepatocellular carcinoma, 
mammary gland adenocarcinoma, melanotic and non-small cell lung cancer cell lines, and human 
fibroblasts as the normal cell line. Compound 4 bearing the trimeric polythiophene acetic acid (tPTAA) 
ligand was also evaluated. 
The rhenium compound 2 showed the best results on the colorectal cancer cell line, excepting 
the melanotic cell line, with a relative IC50 of 88.6 +/- 7.1. The melanotic cell line results were not 
considered due to possible interference of the dark colour in the colorimetric viability assay. Colorectal 
cancer is the third most common cancer in men (10 % of the total) and the second in women (9.2 % of 
the total) worldwide, and the deadliest type of cancer in Portugal (3797 deaths, 15.7% of the total) 
(IARC, 2012).  
Being important to study drug combinations and administration schedules with more efficacy and 
less side-effects than the already existent (Yap et al., 2013), combined therapeutics with some of the 
most used anticancer drugs were performed. 
 Following this line of thinking, combined therapy of compound 2 and cisplatin or doxorubicin was 
performed in colorectal cancer cell line. The same schedule and conditions of treatment was tested for 
compound 4.  
Platinum compounds are usually used in the FOLFOX therapeutics (5-FU, leucovorin, and 
oxaliplatin) for colorectal cancer patients (Carethers, 2008). Furthermore, Re has stabilizing properties 
of the membrane erythrocyte by an antioxidant effect and protect the erythrocytes against toxic agents 
that induce hemolysis. In this way, Re could be used in combination with other cytotoxic drugs, like 
cisplatin, in order to reduce side effects such as anemia and improve the antitumour potencial (Collery 
et al., 2004). The ligand of the compound 2, hexamethylenetetramine (HMT), was also studied as an 
adjuvant to radiation and cisplatin in the treatment of the solid tumours with promising results 
(Masunaga et al., 2010). 
 Other authors studied the administration in vivo of doxorubicin encapsulated into pegylated 
liposomes and the combination with hexamethylenetetramine (HMT), showing promising results 
(Masunaga et al., 2009). 
These observations together justified the study of the rhenium compound 2 combined with 
cisplatin and doxorubicin on the colorectal cancer cell line.  
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The best results of the combined therapy were for compound 2 administration and 24 hours later 
doxorubicin treatment, and vice versa, with a reduction of ~1.5x in the percentage of cell viability in 
relation to doxorubicin alone. The best results for compound 4 were the simultaneous administration of 
4 and cisplatin with a reduction of almost 3x of the percentage of cell viability for cisplatin alone. 
Based on the absorbance values obtained in the spectroscopic titration with calf thymus DNA, the 
value obtained for the binding constant of compound 2 was 5.01 (+/- 1.12)×105M−1. This value is lower 
than those observed for typical classical intercalators, e.g. Kb for ethidium bromide–DNA complex is 
equal to 7×107 M–1 (Ahmadi et al., 2011). Therefore, in addition to the results of the 
electrophoretogram with plasmid DNA was proposed that compound 2 interacts weakly with ct-DNA 
and has a non-covalent mode of binding. Furthermore, the low binding constant ~105 suggests that 
the interaction between the metal complex and DNA might not be intercalative in nature. More studies 
are needed in order to support the results, such as fluorescence measurements and viscosity 
measurements. However, this is an important result since it could indicate other form of action of the 
compound 2 different from the doxorubicin and cisplatin. 
The fluorescence quenching assay of HSA showed a relatively moderate interaction between 
compound 2 and HSA with an average value of binding constant of the protein-quencher complex of 
3.10 (+/- 1.2) x 103 M-1. The binding constant reported by other authors to 5-Fluorouracil was of ∼104 
M−1 at 303 K that was considered in the range suitable for drug transportation (Bakkialakshmi et al., 
2012).  
Comparative proteomic analysis for compound 2 was assessed in the colorectal cancer cell line. 
After 48-hour treatment with compound 2 colon cancer cells apparently are more sensitive and prone 
to death due to the relative abundance of the heat shock proteins, GRP94 and HSP7C, affected and 
also RANG protein, a small GTPase involved in many cellular processes. Compound 2 might indirectly 
induce apoptosis since the relative abundance of the TBA1B protein was altered, and consequently 
microtubule stability and the function of the spindle apparatus can be compromised causing cancer 
cells to arrest and undergo apoptosis. On the other hand, Ezrin was more abundant on colorectal 
cancer cells treated with the compound 2 that in the control, what could be an adaptive response since 
Ezrin has been linked to Akt-mediated cell survival and apoptosis. When Ezrin is absent in colorectal 
cancer cells this leads to the downregulation of X-linked inhibitor of apoptosis protein (Leiphrakpam et 
al., 2014). This response could be inhibiting apoptosis. In addition, PA2G4 overexpression might 
indicate that compound 2 triggers cell death by cell cycle arrest. 
Tumor cell death was evaluated by fluorescence microscopy and flow citometry. Compound 4 
was more effective in killing tumour cells than compound 2, what corroborates the results of the cell 
viability assays. Nevertheless, it seems to be an overestimation of cell death for compound 2. 
Apparently, apoptosis is not the main mechanism of cell death for compound 2 with 4.15 +/-1.16 % of 
apoptotic cells by Hoechst staining and 1.4% of early apoptotic cells and 13.3% of late apoptotic cells 
in flow citometry. This goes in line with the proteomic results, in particular the higher abundance of 
Ezrin. In order to confirm these results other assays are needed such as western blott for specific 
proteins with a role in apoptosis. 
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6 Annex 
 
Table 6.1 Lysis Buffer constitution. 
Lysis Buffer  
Stock Final concentration 
phosphate inhibitor(1) (10x) 1x 
protease inhibitor(2) (5x) 1x 
NP-40(3) (10%, v/v) 2% (v/v) 
Dithiothreitol(4) (10%) 0.1% 
Phenylmethanesulfonyl fluoride(5) (10%) 0.1% 
Tris-NaCl EDTA buffer pH 8.2(6) (5.5x) 1x 
Legend: (1)PhosStop, Roche, Basel, Switzerland; (2)Complete Mini, Roche, Basel, Switzerland; (3)Thermo 
Scientific, Waltham, United States of America; (4) Promega, Madison, United States of America; (5)Sigma, St. 
Louis, United States of America; (6)150mM NaCl (VWR, Radnor, Pennsylvania), 50mM Tris (Sigma, St. Louis, 
United States of America) and 5mM EDTA (Sigma, St. Louis, United States of America). 
 
 
Table 6.2 Rehidration Buffer constitution. 
Rehidration Buffer 
Stock Final concentration 
Urea(1) 7 M 
thioreia(2)  2 M 
Chaps detergent (3) (10%) 2%  
phosphate inhibitor (4) (10%) 1% 
protease inhibitor (5) (5x) 1x 
blue bromophenol (6)  traces 
Legend: (1)Sigma, St. Louis, United States of America; (2)Sigma, St. Louis, United States of America; (3)GE 
healthcare, Wilmington, United States of America; (4)PhosStop, Roche, Basel, Switzerland; (5)Complete Mini, 
Roche, Basel, Switzerland and (6)Riedel-de Haën, Saint Louis, United States of America.Buffer stored in aliquots 
of 500 µL at -20ºC until use.  
 
 
Table 6.3 SDS loading buffer constitution. 
SDS loading buffer 
Concentration stock Final concentration 
glycerol(1) 40% 
SDS(2)  8% 
Tris-HCl(3)  200 mM 
Legend:  (1) Panreac, Barcelona, Spain; (2)  Riedel-de Haën, Saint Louis, United States of America and (3) Merck, 
Whitehouse Station, United States of America. 
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Table 6.4 Poliacrilamide gels constitution. 
Poliacrilamide gels 
 Separation gel Stacking gel 
Stock Volumes Volumes 
Acrylamide/bisacrilamide (1) 4 mL 620 µL 
Distilled water 3.5 mL 3.13 mL 
Tris-HCl 1.5M pH 8.8(2) 2.5 mL ---- 
Ammonium persulfate (10%)(3)    75 µL 50 µL 
Tetramethylethylenediamine(4) 10 µL 5 µL 
Tris-HCl 0.5M pH 6.8(2) --- 1.25 mL 
Legend: Recipe for two 12% poliacrilamide separation gels and two 3.7% stacking gels. (1)30%, Merck, 
Darmstadt, Germany;(2)Calbiochem, Darmstadt, Germany; (3)Biorad, California, United States of America; (4) 
Sigma, Saint Louis, United States of America.  
 
Table 6.5 Electrophoresis buffer. Electrophoresis buffer (10x, pH 8.6-8.8) is prepared in a more concentrated 
solution and then diluted 10x with 0.1% of SDS (20%, p/v) (3) and Milli-Q water up to 1000 mL. 
Electrophoresis buffer (10x) 
Solution  Concentration or volume 
glycerol(1) 1.92 M 
Tris base(2)  250 mM 
Milli-Q water  500 mL 
Legend: (1) Panreac, Barcelona, Spain; (2) Calbiochem, Darmstadt, Germany.  
 
Table 6.6 Staining solution for proteomic gels. 
Staining solution 
 PhasTGel™ Blue R (1) three tablets 
acetic acid (10%, v/v)(2)  1 L 
Milli-Q water  500 mL 
 Legend: (1)GE Healthcare, Wilmington, United States of America; (2)Panreac, Barcelona, Spain.  
 
Table 6.7 Equilibration solution for proteomic strips. 
Equilibration solution  
Solution  Concentration  
 Tris-HCl pH 8.8 (1) 70 mM 
urea(2)  6 M 
Glycerol(3)  30% (v/v) 
SDS(4) 2% (p/v) 
Bromophenol blue(5) traces 
Legend: (1)Calbiochem, Darmstadt, Germany, (2)Scharlau, Barcelona, Spain; (3)Panreac, Barcelona, Spain; (4) 
Riedel-de Haën, Saint Louis, United States of America and (5)Riedel-de Haën, Saint Louis, United States of 
America. 
